Supplemental Material

Table of Contents Supplemental methods 2
Supplemental Table S1: Data sources in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S2: Data Sources integrated within the BC COVID-19 Cohort (BCC19C)7
Supplemental Table S3: Distribution of study subjects by geographic region in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S4: Baseline characteristics by SARS-CoV-2 PCR test results in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S5: Baseline characteristics by vaccination status in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S6: Baseline characteristics by vaccine product in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S7: Province-specific and pooled vaccine effectiveness ≥ 14 days after a first dose and ≥ 7 days after receiving a second dose against hospitalization and death in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S8: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death for mRNA and ChAdOx1 vaccines in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S9: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death \geq 14 days after a first dose (for subjects who received only 1 dose) and \geq 7 days after receiving a second dose by subject characteristics in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S10: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death \geq 14 days after a first dose (for subjects who received only 1 dose) and \geq 7 days after receiving a second dose by vaccine product in Ontario, Quebec, British Columbia, and Manitoba26
Supplemental Table S11: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death \geq 14 days after a first dose (for subjects who received only 1 dose) and \geq 7 days after receiving a second dose by SARS-CoV-2 lineage in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S12: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death by varying dosing intervals among subjects who received 2 doses of an mRNA in Ontario, Quebec, British Columbia, and Manitoba
Supplemental Table S13: Test of heterogeneity for all pooled primary analyses
Supplemental Table S14: Pooled vaccine effectiveness from the sensitivity analyses

Supplemental methods

Extended dosing interval and heterologous COVID-19 vaccination policies in Canada: In view of limited vaccine supply, British Columbia (BC) and Quebec extended the interval between the first and second doses to six weeks and 12 weeks, respectively in January 2021 to maximize one-dose vaccine coverage [1]. Facing similar vaccine supply constraints, other provinces also delayed second dose administration by up to 16 weeks in accordance with a recommendation from Canada's National Advisory Committee on Immunization (NACI) in March 2021 [2]. In view of the safety signal of vaccineinduced immune thrombotic thrombocytopenia associated with ChAdOx1 (AstraZeneca Vaxzevria and COVISHIELD), NACI recommended the use of ChAdOx1 for adults aged ≥55 years in March 2021, and in April 2021 recommended ChAdOx1 for adults aged ≥30 years only when mRNA vaccines were contraindicated or inaccessible [3]. In June 2021, after reviewing the evidence on the interchangeability of authorized COVID-19 vaccines in Canada, NACI recommended that a different mRNA vaccine product could be used for the second dose if the initial mRNA vaccine product was unavailable; and either a ChAdOx1 or an mRNA vaccine product could be used for subsequent dose if the first dose was a ChAdOx1 vaccine [4]. Thereafter, jurisdictions in Canada started implementing heterologous or 'mixand-match' vaccine schedules due to variable supplies of specific vaccine products.

SARS-CoV-2 lineage ascertainment:

SARS-CoV-2 lineage was ascertained from whole genome sequencing or screening tests for N501Y, E484K, K417N, and K417T mutations to group test-positive specimens into mutually exclusive categories. Specimens designated as the B.1.1.7 lineage or having N501Y and E484K mutations were considered Alpha; specimens designated as the B.1.351 lineage or having K417N, N501Y, and E484K mutations were considered Beta; specimens designated as the P.1 lineage or having K417T, N501Y, and E484K mutations were considered Gamma; specimens designated as the B.1.1.7 or P.1 lineage, or having N501Y and E484K mutations were considered Gamma; specimens designated as these could not be separated into Beta or Gamma; and specimens designated as the B.1.617.2 lineage, and in Ontario specimens having N501Y and E484K mutations from geographic locations and dates when B.1.617.2 was known to be predominant through whole genome sequencing were considered Delta [5]. Specimens with earlier variant, or no lineage information, and absence of both N501Y and E484K mutations were considered non-VOC SARS-CoV-2. Information on non-VOC, Beta, and Gamma variants was not available in Quebec.

Statistical analyses (province-specific variations):

In Quebec, information on comorbidity and area-level social determinants of health was missing for approximately 9% and 1% of the study-eligible subjects (n=1,069,031), respectively, and missing not at

random. Thus, only subjects with information on all covariates were included in Quebec. Other provinces included subjects with missing covariate information in the study as a separate category. For subgroup analysis in Quebec, the model for 70–79 years, and Alpha and Delta variants did not converge when all covariates were included in the model and including the entire study period, respectively. To achieve model convergence, the model for 70–79 years was adjusted for sex, biweekly period of test, any comorbidity, number of SARS-CoV-2 tests in previous 3 months, and receipt of influenza vaccination in current or prior influenza season; analysis period was restricted from 28 December 2020 to 30 September 2021 for the Alpha variant and from 26 July 2021 to 30 September 2021 for the Delta variant in Quebec. The primary analysis was conducted by including severe outcomes identified from the provincial notifiable disease reporting system Public Health Case and Contact Management Solution (CCM) in Ontario, and severe outcomes from the COVID-19 surveillance data alone or from both COVID-19 surveillance and administrative data in other provinces.

Category	Information		Province (2021 po	opulation, million)	
		Ontario (14.8)	Quebec (8.6)	British Columbia (5.2)	Manitoba (1.4)
Vaccine	COVID-19 vaccine	COVaxON provincial COVID-19 vaccination management system	Vaccine registry	Provincial Immunization Registry	Public Health Information Management System (PHIMS) - COVID-19- specific database ^a
COVID-19 Cases	Laboratory testing	Ontario Laboratories Information System (OLIS)	Nosotech	Integrated lab data and Provincial Laboratory Information Solution (PLIS)	COVID-19 Lab Test Results data
	Notifiable diseases (with course and outcome)	Public Health Case and Contact Management Solution (CCM)	plateforme Trajectoire de santé publique	COVID-19 case surveillance dataset	PHIMS - Surveillance Case of COVID-19
	Mutations and SARS-CoV-2 lineages	ССМ	Nosotech	Integrated laboratory dataset for COVID-19 and PLIS	PHIMS - Surveillance Case of COVID-19
Outcomes	Death	Reported with case data in CCM	plateforme Trajectoire de santé publique	Vital Statistics	PHIMS - Surveillance Case of COVID-19
		Administrative database: Registered Persons Database (RPDB)	-	COVID-19 case surveillance dataset	-
	Hospitalization, including ICU admission	Reported with case data in CCM	MedEcho	Provincial COVID-19 Monitoring Solution (PCMS)	COVID hospitalization/ICU in surveillance data
				COVID-19 case surveillance dataset	
		Administrative database: Discharge Abstract	-	Discharge Abstract Database (DAD)	-

Supplemental Table S1: Data sources in Ontario, Quebec, British Columbia, and Manitoba

		Database (DAD)			
Covariates	Age	RPDB	Vaccine registry	Integrated laboratory dataset for COVID-19	Manitoba Health Population Registry Data
	Sex	RPDB	Vaccine registry	Integrated laboratory dataset for COVID-19	Manitoba Health Population Registry Data
	Public health unit region based on postal code of residence	RPDB	Vaccine registry	Integrated laboratory dataset for COVID-19	Manitoba Health Population Registry Data
	Biweekly period of test	OLIS	Nosotech	Integrated laboratory dataset for COVID-19	COVID-19 Lab Test Results data
	Number of tests in previous 3 months	OLIS	Nosotech	Integrated laboratory dataset for COVID-19	COVID-19 Lab Test Results data
	Comorbidity	Various registries and cohorts created using algorithms applied to health admin data [6]	Système intégré de surveillance des maladies chroniques du Québec (SISMACQ)	Various registries and cohorts created using algorithms applied to health admin data	Various registries and cohorts created using algorithms applied to health admin data
	Influenza vaccination (physician billing claims)	Ontario Health Insurance Plan (OHIP)	Vaccine registry	Not available	Manitoba Immunization Monitoring System (MIMS)/ Public Health Information Management System (PHIMS)
	Influenza vaccination (pharmacist billing claims)	Ontario Drug Benefit (ODB)	Vaccine registry	Not available	PHIMS
Median neighbourhood income		2016 Census	2016 Census	Information on neighbourhood income not available; used Material Deprivation Index (average household income; unemployment rate; and high school education rate) from 2016	2016 Census

			Census		
Proportion working	2016 Census	2016 Census	2016 Census	2016 Census	
in non-health					
essential services					
Persons per dwelling	2016 Census	2016 Census	2016 Census	2016 Census	
quintile					
Self-identified visible	2016 Census	2016 Census	2016 Census	2016 Census	
minority quintile					

^aAstraZeneca Vaxzevria and COVISHIELD vaccines were reported only as ChAdOx1

British Columbia Centre for Disease Control (BCCDC), Provincial Heath Services	Data Date Ranges
Authority (PHSA) and Regional Health Authority data sources	Data Date Kanges
Integrated COVID-19 laboratory dataset (SARS-CoV2 tests from private/public labs) [7]	Jan,2020-onward
COVID-19 surveillance case data (information collected on all probable/confirmed cases as	Ing 2020 annual
part of public health follow up) [8]	Jan,2020-onward
Provincial COVID-19 Monitoring Solution (critical and non-critical care hospital census	Ing 2020 annual
data) [9]	Jan,2020-onward
Provincial Immunizations Registry (COVID-19 vaccination data) [10]	Dec,2020-onward
Provincial Laboratory Information Solution (laboratory tests from private/public labs) [11]	Jan,2020-onward
Public Health Reporting Data warehouse (Influenza laboratory tests) [12]	Jan,2008-onward
Emergency department visits (hospital-based and community-based ambulatory care)	Mar,2020-onward
Ministry of Health (MoH) Administrative Data Sources	Data Date Ranges
Client Roster (CR) (registry of enrollment in the universal public health insurance plan	2008/9-onward
including residential history) [13]	
Discharge Abstracts Database (DAD) (hospital discharge records) [14]	2008/9-onward
Medical Services Plan (MSP) (physician diagnostic and billing data for services provided	2008/9-onward
through universal public health insurance plan)[15]	2008/9-011ward
PharmaNet (Pharma) (prescription drugs dispensed from community pharmacies, includes	2008/9-onward
medications covered by public and private insurance plans) [16]	2008/9-011ward
BC Vital Statistics (VS) (deaths registry) [17]	2008/9-onward
National Ambulatory Care Reporting System (NACRS) (hospital-based and community-	2011/12-onward
based ambulatory care) [18]	2011/12-011walu
Chronic Disease Registry [19]	2008/9-2018/19
811 Calls (respiratory calls only) [20]	2014-onward
Health System Matrix [21]	2018/19-onward
Population Grouper Methodology [22]	2008/9-onward

Supplemental Table S2: Data Sources integrated within the BC COVID-19 Cohort (BCC19C)

O	ntario	Qu	ebec	Britis	sh Columbia	Manitoba	
Public health unit region	n (%)	Heath region	n (%)	Health authority	n (%)	Regional health authority	n (%)
Central East	55,503 (10.0)	Bas-Saint- Laurent	20,278 (2.1)	Fraser	379,347 (43.3)	Interlake-Eastern	11,779 (9.8)
Central West	98,349 (17.6)	Saguenay – Lac- Saint-Jean	35,083 (3.7)	Interior	136,410 (15.6)	Northern	8,146 (6.8)
Durham	27,121 (4.9)	Capitale- Nationale	110,311 (11.6)	Island	110,506 (12.6)	Prairie Mountain	16,606 (13.8)
Eastern	26,841 (4.8)	Mauricie-et- Centre-du- Québec	65,919 (6.9)	Northern	33,098 (3.8)	Southern Health- Santé Sud	12,485 (10.4)
North	53,519 (9.6)	Estrie	55,962 (5.9)	Vancouver Coastal	199,179 (22.7)	Winnipeg	71,097 (59.0)
Ottawa	7,428 (1.3)	Montréal	188,802 (19.8)	Unknown/ missing	17,857 (2.0)	Public Trustee/ In CFS care	357 (0.3)
Peel	73,898 (13.3)	Outaouais	37,842 (4.0)				
South West	67,253 (12.1)	Abitibi- Témiscamingue	15,622 (1.6)				
Toronto	105,920 (19.0)	Côte-Nord	9,099 (1.0)				
York	39,132 (7.0)	Nord-du-Québec	1,281 (0.1)				
Unknown/ missing	2,256 (0.4)	Gaspésie – Îles- de-la-Madeleine	9,807 (1.0)				
		Chaudière- Appalaches	52,869 (5.5)				
		Laval	44,321 (4.6)				
		Lanaudière	66,461 (7.0)				
		Laurentides	73,223 (7.7)				
		Montérégie	165,813 (17.4)				
		Nunavik	654 (0.1)				
		Terres-Cries-de- la-Baie-James	861 (0.1)				

Supplemental Table S3: Distribution of study subjects by geographic region in Ontario, Quebec, British Columbia, and Manitoba

Characteristic	On	tario	Qu	ebec	British	Columbia	Man	itoba
	SARS-CoV-2- positive, n (%) ^a (N=17,437)	SARS-CoV-2- negative, n (%) ^a (N=539,783)	SARS-CoV-2- positive, n (%) ^a (N=7,854)	SARS-CoV-2- negative, n (%) ^a (N=946,354)	SARS-CoV-2- positive, n (%) ^a (N=5,928)	SARS-CoV-2- negative, n (%) ^a (N=870,469)	SARS-CoV-2- positive, n (%) ^a (N=2,201)	SARS-CoV-2- negative, n (%) ^a (N=118,270)
COVID-19 hospitalization	16,726	-	7,217	-	5,706	-	2,127	-
COVID-19-associated death	3,268	-	1,491	-	766	-	317	-
Received ≥1 dose of COVID-19 vaccine	2,859 (16.4)	232,711 (43.1)	1,040 (13.2)	439,458 (46.4)	1,185 (20.0)	348,062 (40.0)	346 (15.7)	52,682 (44.5)
Received 2 doses of COVID-19 vaccine	316 (1.8)	154,118 (28.6)	176 (2.2)	229,820 (24.3)	252 (4.3)	205,797 (23.6)	75 (3.4)	35,035 (29.6)
Age (years), mean (standard deviation)	62 (18)	43 (17)	65 (18)	47 (17)	60 (18)	44 (18)	54 (20)	44 (17)
Age group (years)								
18–29	804 (4.6)	140,684 (26.1)	278 (3.5)	175,466 (18.5)	331 (5.6)	209,917 (24.1)	344 (15.6)	30,367 (25.7)
30-39	1,401 (8.0)	127,015 (23.5)	576 (7.3)	216,808 (22.9)	621 (10.5)	196,562 (22.6)	293 (13.3)	28,183 (23.8)
40-49	1,966 (11.3)	90,774 (16.8)	795 (10.1)	184,237 (19.5)	753 (12.7)	142,650 (16.4)	296 (13.4)	20,606 (17.4)
50-59	3,217 (18.4)	77,582 (14.4)	1,302 (16.6)	137,422 (14.5)	1,040 (17.5)	122,930 (14.1)	373 (16.9)	16,262 (13.7)
60–69	3,441 (19.7)	55,067 (10.2)	1,553 (19.8)	125,079 (13.2)	1,233 (20.8)	98,163 (11.3)	369 (16.8)	12,522 (10.6)
70–79	3,224 (18.5)	29,780 (5.5)	1,605 (20.4)	72,594 (7.7)	1,055 (17.8)	61,185 (7.0)	301 (13.7)	6,630 (5.6)
≥80	3,384 (19.4)	18,881 (3.5)	1,745 (22.2)	34,748 (3.7)	895 (15.1)	39,062 (4.5)	225 (10.2)	3,700 (3.1)
Male sex	9,688 (55.6)	227,350 (42.1)	4,447 (56.6)	378,787 (40.0)	3,413 (57.6)	391,259 (44.9)	1,018 (46.3)	50,762 (42.9)
Biweekly period of test								
14 Dec 2020 to 27 Dec 2020	1,044 (6.0)	26,416 (4.9)	944 (12.0)	40,162 (4.2)	230 (3.9)	45,742 (5.3)	146 (6.6)	5,564 (4.7)
28 Dec 2020 to 10 Jan 2021	1,450 (8.3)	24,642 (4.6)	1,158 (14.7)	38,885 (4.1)	279 (4.7)	44,287 (5.1)	129 (5.9)	4,828 (4.1)
11 Jan 2021 to 24 Jan 2021	1,091 (6.3)	24,367 (4.5)	839 (10.7)	41,164 (4.3)	134 (2.3)	25,817 (3.0)	121 (5.5)	4,966 (4.2)
25 Jan 2021 to 7 Feb 2021	781 (4.5)	21,978 (4.1)	508 (6.5)	41,684 (4.4)	143 (2.4)	18,705 (2.1)	75 (3.4)	4,819 (4.1)
8 Feb 2021 to 21 Feb 2021	632 (3.6)	22,204 (4.1)	384 (4.9)	47,729 (5.0)	272 (4.6)	46,664 (5.4)	49 (2.2)	4,478 (3.8)
22 Feb 2021 to 7 Mar 2021	641 (3.7)	27,363 (5.1)	346 (4.4)	49,256 (5.2)	237 (4.0)	42,970 (4.9)	49 (2.2)	4,825 (4.1)
8 Mar 2021 to 21 Mar 2021	966 (5.5)	29,155 (5.4)	376 (4.8)	51,409 (5.4)	274 (4.6)	45,938 (5.3)	52 (2.4)	4,965 (4.2)

Supplemental Table S4: Baseline characteristics by SARS-CoV-2 PCR test results in Ontario, Quebec, British Columbia, and Manitoba

22 Mar 2021 to 4 Apr	1,642 (9.4)	32,418 (6.0)	529 (6.7)	62,676 (6.6)	303 (5.1)	43,106 (5.0)	58 (2.6)	5,593 (4.7)
2021								
5 Apr 2021 to 18 Apr 2021	2,662 (15.3)	39,495 (7.3)	741 (9.4)	72,641 (7.7)	446 (7.5)	50,770 (5.8)	80 (3.6)	7,215 (6.1)
19 Apr 2021 to 2 May 2021	2,111 (12.1)	37,679 (7.0)	519 (6.6)	61,383 (6.5)	621 (10.5)	62,412 (7.2)	170 (7.7)	8,921 (7.5)
3 May 2021 to 16 May 2021	1,380 (7.9)	28,199 (5.2)	329 (4.2)	55,154 (5.8)	539 (9.1)	53,747 (6.2)	296 (13.4)	7,986 (6.8)
17 May 2021 to 30 May 2021	766 (4.4)	17,827 (3.3)	194 (2.5)	38,063 (4.0)	392 (6.6)	43,436 (5.0)	306 (13.9)	7,049 (6.0)
31 May 2021 to 13 Jun 2021	441 (2.5)	14,696 (2.7)	75 (1.0)	33,818 (3.6)	231 (3.9)	32,209 (3.7)	217 (9.9)	5,509 (4.7)
14 Jun 2021 to 27 Jun 2021	235 (1.3)	14,267 (2.6)	34 (0.4)	41,365 (4.4)	122 (2.1)	26,515 (3.0)	90 (4.1)	4,088 (3.5)
28 Jun 2021 to 11 Jul 2021	162 (0.9)	11,944 (2.2)	23 (0.3)	36,798 (3.9)	85 (1.4)	23,236 (2.7)	74 (3.4)	2,962 (2.5)
12 Jul 2021 to 25 Jul 2021	92 (0.5)	15,394 (2.9)	21 (0.3)	28,961 (3.1)	39 (0.7)	18,251 (2.1)	49 (2.2)	3,104 (2.6)
26 Jul 2021 to 8 Aug 2021	146 (0.8)	22,677 (4.2)	52 (0.7)	28,091 (3.0)	43 (0.7)	19,691 (2.3)	37 (1.7)	3,901 (3.3)
9 Aug 2021 to 22 Aug 2021	288 (1.7)	30,093 (5.6)	116 (1.5)	30,752 (3.2)	119 (2.0)	27,018 (3.1)	27 (1.2)	4,985 (4.2)
23 Aug 2021 to 5 Sep 2021	406 (2.3)	31,616 (5.9)	216 (2.8)	38,390 (4.1)	296 (5.0)	41,510 (4.8)	41 (1.9)	6,700 (5.7)
6 Sep 2021 to 19 Sep 2021	334 (1.9)	32,458 (6.0)	295 (3.8)	54,638 (5.8)	384 (6.5)	53,085 (6.1)	55 (2.5)	7,684 (6.5)
20 Sep 2021 to 30 Sep 2021	167 (1.0)	34,895 (6.5)	155 (2.0)	53,335 (5.6)	739 (12.5)	105,360 (12.1)	80 (3.6)	8,128 (6.9)
Number of tests in previous 3 months								
0	14,599 (83.7)	391,672 (72.6)	6,104 (77.7)	708,447 (74.9)	5,106 (86.1)	735,463 (84.5)	1,751 (79.6)	88,031 (74.4)
1	1,860 (10.7)	103,669 (19.2)	984 (12.5)	170,316 (18)	650 (11.0)	102,182 (11.7)	311 (14.1)	24,623 (20.8)
≥2	978 (5.6)	44,442 (8.2)	766 (9.8)	67,591 (7.1)	172 (2.9)	32,824 (3.8)	139 (6.3)	5,616 (4.7)
Any comorbidity ^b	13,343 (76.5)	248,898 (46.1)	5,260 (67.0)	302,647 (32.0)	3,947 (66.6)	326,652 (37.5)	1,431 (65.0)	45,672 (38.6)
Receipt of 2019-2020 and/or 2020-2021 influenza vaccination	6,783 (38.9)	178,657 (33.1)	2,835 (36.1)	258,090 (27.3)	Not available	Not available	767 (34.8)	55,480 (46.9)
Neighbourhood income quintile ^c								
1 (lowest)	5,678 (32.6)	95,132 (17.6)	2,164 (27.6)	164,636 (17.4)	1,362 (23.0)	110,426 (12.7)	881 (40.0)	21,057 (17.8)

2	3,824 (21.9)	104,266 (19.3)	1,856 (23.6)	183,802 (19.4)	1,259 (21.2)	150,398 (17.3)	389 (17.7)	22,919 (19.4)
3	3,319 (19.0)	108,434 (20.1)	1,553 (19.8)	195,284 (20.6)	1,110 (18.7)	164,168 (18.9)	356 (16.2)	22,874 (19.3)
4	2,524 (14.5)	112,380 (20.8)	1255 (16.0)	202,334 (21.4)	928 (15.7)	186,825 (21.5)	316 (14.4)	22,801 (19.3)
5 (highest)	2,012 (11.5)	117,116 (21.7)	1,026 (13.1)	200,298 (21.2)	744 (12.6)	169,532 (19.5)	193 (8.8)	23,936 (20.2)
Unknown/missing	80 (0.5)	2,455 (0.5)	-	-	525 (8.9)	89,120 (10.2)	66 (3.0)	4,683 (4.0)
Essential workers								
quintile ^d								
1 (0%-32.5%)	2,679 (15.4)	100,570 (18.6)	1,601 (20.4)	218,640 (23.1)	421 (7.1)	94,738 (10.9)	598 (27.2)	24,735 (20.9)
2 (32.5%-42.3%)	3,313 (19.0)	122,840 (22.8)	1,854 (23.6)	216,807 (22.9)	867 (14.6)	160,668 (18.5)	425 (19.3)	27,559 (23.3)
3 (42.3%-49.8%)	3,454 (19.8)	112,426 (20.8)	1,661 (21.1)	193,624 (20.5)	918 (15.5)	151,706 (17.4)	393 (17.9)	22,714 (19.2)
4 (50.0%-57.5%)	3,666 (21.0)	105,236 (19.5)	1,519 (19.3)	169,753 (17.9)	1,136 (19.2)	136,131 (15.6)	392 (17.8)	22,179 (18.8)
5 (57.5%-100%)	4,226 (24.2)	94,953 (17.6)	1,219 (15.5)	147,530 (15.6)	1,300 (21.9)	123,183 (14.2)	354 (16.1)	19,244 (16.3)
Unknown/missing	99 (0.6)	3,758 (0.7)	-	-	1,286 (21.7)	204,043 (23.4)	28 (1.3)	357 (0.3)
Persons per dwelling								
quintile ^e								
1 (0–2.1)	3,410 (19.6)	98,120 (18.2)	1,745 (22.2)	190,315 (20.1)	1,368 (23.1)	179,935 (20.7)	625 (28.4)	29,676 (25.1)
2 (2.2–2.4)	2,619 (15.0)	97,786 (18.1)	1,086 (13.8)	142,283 (15.0)	941 (15.9)	146,373 (16.8)	279 (12.7)	19,304 (16.3)
3 (2.5–2.6)	1,945 (11.2)	69,988 (13.0)	1,337 (17.0)	164,333 (17.4)	956 (16.1)	151,365 (17.4)	264 (12.0)	19,820 (16.8)
4 (2.7–3.0)	4,107 (23.6)	128,988 (23.9)	1,833 (23.3)	238,048 (25.2)	902 (15.2)	157,131 (18.1)	386 (17.5)	25,032 (21.2)
5 (3.1–5.7)	5,249 (30.1)	140,991 (26.1)	1,853 (23.6)	211,375 (22.3)	1,605 (27.1)	184,599 (21.2)	608 (27.6)	22,599 (19.1)
Unknown/missing	107 (0.6)	3,910 (0.7)	-	-	156 (2.6)	51,066 (5.9)	28 (1.3)	357 (0.3)
Self-identified visible								
minority quintile ^f								
1 (0.0%-2.2%)	1,316 (7.5)	91,833 (17.0)	1,200 (15.3)	222,658 (23.5)	853 (14.4)	99,619 (11.4)	456 (20.7)	17,833 (15.1)
2 (2.2%-7.5%)	1,651 (9.5)	100,772 (18.7)	783 (10.0)	147,473 (15.6)	962 (16.2)	146,322 (16.8)	459 (20.9)	22,735 (19.2)
3 (7.5%–18.7%)	2,512 (14.4)	99,293 (18.4)	1,222 (15.6)	217,522 (23.0)	1,050 (17.7)	177,798 (20.4)	274 (12.4)	24,072 (20.4)
4 (18.7%–43.5%)	4,225 (24.2)	110,556 (20.5)	1,664 (21.2)	197,633 (20.9)	1,205 (20.3)	203,173 (23.3)	375 (17.0)	25,918 (21.9)
5 (43.5%–100%)	7,634 (43.8)	133,580 (24.7)	2,985 (38.0)	161,068 (17.0)	1,705 (28.8)	193,488 (22.2)	598 (27.2)	25,873 (21.9)
Unknown/missing	99 (0.6)	3,749 (0.7)	-	-	153 (2.6)	50,069 (5.8)	28 (1.3)	357 (0.3)

^aProportion reported, unless stated otherwise.

^bComorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

"Neighbourhood income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income. Material deprivation index quintile used in British Columbia; quintile 1 represents 'most deprived' and quintile 5 represents 'least deprived'.

^dPercentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

^eRange of persons per dwelling.

Percentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

Characteristic	On	tario	Que	ebec	British (Columbia	Man	itoba
	Received ≥1	Unvaccinated,						
	dose, n (%) ^a	n (%) ^a	dose, n (%) ^a	n (%) ^a	dose, n (%) ^a	n (%) ^a	dose, n (%) ^a	n (%) ^a
	(N=235,570)	(N=321,650)	(N=440,498)	(N=513,710)	(N=349,247)	(N=527,150)	(N=53,028)	(N=67,443)
Age (years), mean (standard	45 (19)	43 (17)	49 (18)	45 (16)	48 (19)	43 (17)	46 (18)	42 (16)
deviation)								
Age group (years)								
18–29	54,047 (22.9)	87,441 (27.2)	7,6075 (17.3)	99,669 (19.4)	67,740 (19.4)	142,508 (27.0)	12,200 (23.0)	18,511 (27.4)
30–39	53,454 (22.7)	74,962 (23.3)	89,211 (20.3)	128,173 (25)	70,671 (20.2)	126,512 (24.0)	11,692 (22.0)	16,784 (24.9)
40–49	37,775 (16.0)	54,965 (17.1)	77,354 (17.6)	107,678 (21.0)	55,917 (16.0)	87,486 (16.6)	9,080 (17.1)	11,822 (17.5)
50–59	33,292 (14.1)	47,507 (14.8)	62,394 (14.2)	76,330 (14.9)	50,322 (14.4)	73,648 (14.0)	7,601 (14.3)	9,034 (13.4)
60–69	28,015 (11.9)	30,493 (9.5)	66,572 (15.1)	60,060 (11.7)	46,080 (13.2)	53,316 (10.1)	6,620 (12.5)	6,271 (9.3)
70–79	16,818 (7.1)	16,186 (5.0)	45,145 (10.2)	29,054 (5.7)	339,31 (9.7)	28,309 (5.4)	3,688 (7.0)	3,243 (4.8)
≥80	12,169 (5.2)	10,096 (3.1)	23,747 (5.4)	12,746 (2.5)	24,586 (7.0)	15,371 (2.9)	2,147 (4.0)	1,778 (2.6)
Male sex	93,281 (39.6)	143,757 (44.7)	170,763 (38.8)	212,471 (41.4)	145,873 (41.8)	248,799 (47.2)	21,685 (40.9)	30,095 (44.6)
Biweekly period of test								
14 Dec 2020 to 27 Dec 2020	13 (0.0)	27,447 (8.5)	105 (0.0)	41,001 (8.0)	276 (0.1)	45,696 (8.7)	11 (0.0)	5,699 (8.5)
28 Dec 2020 to 10 Jan 2021	266 (0.1)	25,826 (8.0)	587 (0.1)	39,456 (7.7)	1,204 (0.3)	43,362 (8.2)	19 (0.0)	4,938 (7.3)
11 Jan 2021 to 24 Jan 2021	894 (0.4)	24,564 (7.6)	1,747 (0.4)	40,256 (7.8)	1,522 (0.4)	24,429 (4.6)	78 (0.1)	5,009 (7.4)
25 Jan 2021 to 7 Feb 2021	1,077 (0.5)	21,682 (6.7)	2,190 (0.5)	40,002 (7.8)	1,392 (0.4)	17,456 (3.3)	133 (0.3)	4,761 (7.1)
8 Feb 2021 to 21 Feb 2021	975 (0.4)	21,861 (6.8)	2,666 (0.6)	45,447 (8.8)	3,366 (1.0)	43,570 (8.3)	132 (0.2)	4,395 (6.5)
22 Feb 2021 to 7 Mar 2021	1,388 (0.6)	26,616 (8.3)	3,330 (0.8)	46,272 (9)	2,673 (0.8)	40,534 (7.7)	175 (0.3)	4,699 (7.0)
8 Mar 2021 to 21 Mar 2021	2,532 (1.1)	27,589 (8.6)	4,863 (1.1)	46,922 (9.1)	3,389 (1.0)	428,23 (8.1)	316 (0.6)	4,701 (7.0)
22 Mar 2021 to 4 Apr 2021	4,683 (2.0)	29,377 (9.1)	8,460 (1.9)	54,745 (10.7)	4,771 (1.4)	38,638 (7.3)	533 (1.0)	5,118 (7.6)
5 Apr 2021 to 18 Apr 2021	8,713 (3.7)	33,444 (10.4)	14,720 (3.3)	58,662 (11.4)	7,355 (2.1%)	43,861 (8.3%)	1,152 (2.2)	6,143 (9.1)
19 Apr 2021 to 2 May 2021	11,941 (5.1)	27,849 (8.7)	21,751 (4.9)	40,151 (7.8)	12,952 (3.7)	50,081 (9.5)	2,474 (4.7)	6,617 (9.8)
3 May 2021 to 16 May 2021	13,234 (5.6)	16,345 (5.1)	27,484 (6.2)	27,999 (5.5)	17,208 (4.9)	37,078 (7.0)	3,290 (6.2)	4,992 (7.4)
17 May 2021 to 30 May 2021	11,422 (4.8)	7,171 (2.2)	26,631 (6.0)	11,626 (2.3)	18,934 (5.4)	24,894 (4.7)	4,490 (8.5)	2,865 (4.2)
31 May 2021 to 13 Jun 2021	11,059 (4.7)	4,078 (1.3)	29,057 (6.6)	4,836 (0.9)	19,715 (5.6)	12,725 (2.4)	3,821 (7.2)	1,905 (2.8)
14 Jun 2021 to 27 Jun 2021	11,426 (4.9)	3,076 (1.0)	37,785 (8.6)	3,614 (0.7)	19,311 (5.5)	7,326 (1.4)	3,081 (5.8)	1,097 (1.6)
28 Jun 2021 to 11 Jul 2021	9,814 (4.2)	2,292 (0.7)	33,942 (7.7)	2,879 (0.6)	17,325 (5.0)	5,996 (1.1)	2,365 (4.5)	671 (1.0)
12 Jul 2021 to 25 Jul 2021	12,741 (5.4)	2,745 (0.9)	26,855 (6.1)	21,27 (0.4)	1,3687 (3.9)	4,603 (0.9)	2,574 (4.9)	579 (0.9)
26 Jul 2021 to 8 Aug 2021	19,382 (8.2)	3,441 (1.1)	26,235 (6)	1,908 (0.4)	15,247 (4.4)	4,487 (0.9)	3,355 (6.3)	583 (0.9)
9 Aug 2021 to 22 Aug 2021	26,121 (11.1)	4,260 (1.3)	29,093 (6.6)	1,775 (0.3)	21,378 (6.1)	5,759 (1.1)	4,426 (8.3)	586 (0.9)
23 Aug 2021 to 5 Sep 2021	27,686 (11.8)	4,336 (1.3)	37,009 (8.4)	1,597 (0.3)	33,339 (9.5)	8,467 (1.6)	6,035 (11.4)	706 (1.0)
6 Sep 2021 to 19 Sep 2021	28,869 (12.3)	3,923 (1.2)	53,400 (12.1)	1,533 (0.3)	43,886 (12.6)	9,583 (1.8)	7,035 (13.3)	704 (1.0)
20 Sep 2021 to 30 Sep 2021	31,334 (13.3)	3,728 (1.2)	52,588 (11.9)	902 (0.2)	90,317 (25.9)	15,782 (3.0)	7,533 (14.2)	675 (1.0)
Number of tests in previous 3								
months								

Supplemental Table S5: Baseline characteristics by vaccination status in Ontario, Quebec, British Columbia, and Manitoba

0	1(0,0(1,(71,2)	020 010 (74 1)	207 222 (74 2)	207 210 (75 4)	071 (50 (77.0)	469.017 (90.0)	20.560 (74.5)	50 012 (74 5)
0	168,061 (71.3)	238,210 (74.1)	327,233 (74.3)	387,318 (75.4)	271,652 (77.8)	468,917 (89.0)	39,569 (74.6)	50,213 (74.5)
1	45,235 (19.2)	60,294 (18.7)	7,6736 (17.4)	94,564 (18.4)	55,491 (15.9)	47,341 (9.0)	11,047 (20.8)	13,887 (20.6)
<u>≥</u> 2	22,274 (9.5)	23,146 (7.2)	36,529 (8.3)	31,828 (6.2)	22,104 (6.3)	10,892 (2.1)	2,412 (4.5)	3,343 (5.0)
Any comorbidity ^b	114,748 (48.7)	147,493 (45.9)	158,295 (35.9)	149,612 (29.1)	151,206 (43.3)	179,393 (34.0)	22,095 (41.7)	25,008 (37.1)
Receipt of 2019-2020 and/or	93,962 (39.9)	91,478 (28.4)	147,342 (33.4)	113,583 (22.1)	Not available	Not available	29,224 (55.1)	27,023 (40.1)
2020-2021 influenza								
vaccination								
Neighbourhood income								
quintile ^c								
1 (lowest)	39,233 (16.7)	61,577 (19.1)	7,3547 (16.7)	93,253 (18.2)	42,888 (12.3)	68,900 (13.1)	8,832 (16.7)	13,106 (19.4)
2	44,969 (19.1)	63,121 (19.6)	84,055 (19.1)	101,603 (19.8)	60,126 (17.2)	91,531 (17.4)	9,918 (18.7)	13,390 (19.9)
3	48,229 (20.5)	63,524 (19.7)	89,999 (20.4)	106,838 (20.8)	66,874 (19.1)	98,404 (18.7)	10,393 (19.6)	12,837 (19.0)
4	49,665 (21.1)	65,239 (20.3)	94,224 (21.4)	109,365 (21.3)	78,876 (22.6)	108,877 (20.7)	10,341 (19.5)	12,776 (18.9)
5 (highest)	52,536 (22.3)	66,592 (20.7)	98,673 (22.4)	102,651 (20)	70,720 (20.2)	99,556 (18.9)	11,218 (21.2)	12,911 (19.1)
Unknown/missing	938 (0.4)	1,597 (0.5)	-	-	29,763 (8.5)	59,882 (11.4)	2,326 (4.4)	2,423 (3.6)
Essential workers quintile ^d								
1 (0%-32.5%)	46,555 (19.8)	56,694 (17.6)	108,031 (24.5)	112,210 (21.8)	39,889 (11.4)	55,270 (10.5)	11,860 (22.4)	13,473 (20.0)
2 (32.5%-42.3%)	56,274 (23.9)	69,879 (21.7)	102,009 (23.2)	116,652 (22.7)	67,543 (19.3)	93,992 (17.8)	12,581 (23.7)	15,403 (22.8)
3 (42.3%-49.8%)	49,376 (21.0)	66,504 (20.7)	88,769 (20.2)	106,516 (20.7)	63,453 (18.2)	89,171 (16.9)	9,984 (18.8)	13,123 (19.5)
4 (50.0%-57.5%)	44,485 (18.9)	64,417 (20.0)	7,6257 (17.3)	95,015 (18.5)	54,985 (15.7)	82,282 (15.6)	9,648 (18.2)	12,923 (19.2)
5 (57.5%-100%)	37,474 (15.9)	61,705 (19.2)	65,432 (14.9)	83,317 (16.2)	48,061 (13.8)	76,422 (14.5)	8,088 (15.3)	11,510 (17.1)
Unknown/missing	1,406 (0.6)	2,451 (0.8)	-	-	75,316 (21.6)	130,013 (24.7)	150 (0.3)	235 (0.3)
Persons per dwelling quintile ^e								
1 (0–2.1)	40,938 (17.4)	60,592 (18.8)	87,054 (19.8)	105,006 (20.4)	75,494 (21.6)	105,809 (20.1)	13,178 (24.9)	17,123 (25.4)
2 (2.2–2.4)	39,935 (17.0)	60,470 (18.8)	66,161 (15.0)	77,208 (15.0)	59,910 (17.2)	87,404 (16.6)	8,551 (16.1)	11,032 (16.4)
3 (2.5–2.6)	29,449 (12.5)	42,484 (13.2)	76,064 (17.3)	89,606 (17.4)	62,129 (17.8)	90,192 (17.1)	8,785 (16.6)	11,299 (16.8)
4 (2.7–3.0)	57,106 (24.2)	75,989 (23.6)	109,072 (24.8)	130,809 (25.5)	64,785 (18.6)	93,248 (17.7)	11,226 (21.2)	14,192 (21.0)
5 (3.1–5.7)	66,656 (28.3)	79,584 (24.7)	102,147 (23.2)	111,081 (21.6)	74,026 (21.2)	112,178 (21.3)	10,421 (19.7)	12,786 (19.0)
Unknown/missing	1,486 (0.6)	2,531 (0.8)	-	-	12,903 (3.7)	38,319 (7.3)	150 (0.3)	235 (0.3)
Self-identified visible minority								· · ·
quintile ^f								
1 (0.0%–2.2%)	36,144 (15.3)	57,005 (17.7)	102,373 (23.2)	121,485 (23.6)	42,165 (12.1)	58,307 (11.1)	8,028 (15.1)	10,261 (15.2)
2 (2.2%-7.5%)	40,698 (17.3)	61,725 (19.2)	67,066 (15.2)	81,190 (15.8)	61,771 (17.7)	85,513 (16.2)	10,158 (19.2)	13,036 (19.3)
3 (7.5%–18.7%)	43,069 (18.3)	58,736 (18.3)	99,999 (22.7)	118,745 (23.1)	73,099 (20.9)	105,749 (20.1)	10,946 (20.6)	13,400 (19.9)
4 (18.7%-43.5%)	50,189 (21.3)	64,592 (20.1)	94,020 (21.3)	105,277 (20.5)	83,457 (23.9)	120,921 (22.9)	11,547 (21.8)	14,746 (21.9)
5 (43.5%–100%)	64,066 (27.2)	77,148 (24.0)	77,040 (17.5)	87,013 (16.9)	76,264 (21.8)	118,929 (22.6)	11,482 (21.7)	14,989 (22.2)
Unknown/missing	1,404 (0.6)	2,444 (0.8)	-	-	12,491 (3.6)	37,731 (7.2)	150 (0.3)	235 (0.3)
^a Droportion reported unless stated oth		_,(0.0)	1			=======	100 (0.0)	200 (0.0)

^aProportion reported, unless stated otherwise. ^bComorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

"Neighbourhood income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income. Material deprivation index quintile used in British Columbia; quintile 1 represents 'most deprived' and quintile 5 represents 'least deprived'.

^dPercentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

^eRange of persons per dwelling.

^fPercentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

Characteristic	1	Ontario			Quebec	Ontario, Que		ritish Columb			Manitoba	
	Received ≥1 dose BNT162b2 , n (%) ^a (N=151,08	Received ≥1 dose mRNA- 1273, n (%) ^a (N=42,994)	Received ≥1 dose AstraZene ca/COVIS HIELD, n (%) ^a	Received ≥1 dose BNT162b2 , n (%) ^a (N=316,53	Received ≥1 dose mRNA- 1273, n (%) ^a (N=86,177)	Received ≥1 dose AstraZenec a/COVISH IELD, n (%) ^a	Received ≥1 dose BNT162b 2, n (%) ^a (N=240,04	Received ≥1 dose mRNA- 1273, n (%) ^a (N=64,367)	Received ≥1 dose AstraZene ca/COVIS HIELD, n (%) ^a	Received ≥1 dose BNT162b2, n (%) ^a (N=34,622)	Received ≥1 dose mRNA- 1273, n (%) ^a (N=12,480)	Received ≥1 dose AstraZene ca/COVIS HIELD, n (%) ^a
Age (years), mean (standard deviation)	6) 46 (19)	44 (19)	(N=10,940) 57 (9)	5) 48 (19)	46 (18)	(N=37,786) 60 (11)	3) 48 (20)	46 (19)	(N=17,748) 51 (11)	45 (19)	43 (19)	(N=5,916) 51 (10)
Age group (years)												
18–29	35,733 (23.7)	11,078 (25.8)	16 (0.1)	57,655 (18.2)	18,187 (21.1)	233 (0.6)	49,819 (20.8)	14,667 (22.8)	729 (4.1)	8,545 (24.7)	3,594 (28.8)	59 (1.0)
30–39	35,444 (23.5)	10,651 (24.8)	278 (2.5)	68,649 (21.7)	20,213 (23.5)	349 (0.9)	49,858 (20.8)	14,246 (22.1)	2,201 (12.4)	8,165 (23.6)	3,086 (24.7)	439 (7.4)
40-49	22,333 (14.8)	6,368 (14.8)	2,259 (20.6)	57,415 (18.1)	14,344 (16.6)	5,595 (14.8)	36,158 (15.1)	9,552 (14.8)	4,525 (25.5)	4,665 (13.5)	1,678 (13.4)	2,735 (46.2)
50–59	19,690 (13.0)	5,641 (13.1)	3,179 (29.1)	34,003 (10.7)	10,209 (11.8)	18,182 (48.1)	30,341 (12.6)	8,442 (13.1)	5,954 (33.5)	4,438 (12.8)	1,533 (12.3)	1,629 (27.5)
60–69	16,006 (10.6)	4,047 (9.4)	4,661 (42.6)	48,068 (15.2)	12,306 (14.3)	6,198 (16.4)	28,555 (11.9)	7,974 (12.4)	4,128 (23.3)	4,544 (13.1)	1,231 (9.9)	842 (14.2)
70–79	12,703 (8.4)	2,602 (6.1)	500 (4.6)	32,626 (10.3)	6,782 (7.9)	5,737 (15.2)	26,078 (10.9)	5,345 (8.3)	174 (1.0)	2,776 (8.0)	779 (6.2)	133 (2.2)
≥80	9,177 (6.1)	2,607 (6.1)	47 (0.4)	18,119 (5.7)	4,136 (4.8)	1,492 (3.9)	19,234 (8.0)	4,141 (6.4)	37 (0.2)	1,489 (4.3)	579 (4.6)	79 (1.3)
Male sex	56,434 (37.4)	17,833 (41.5)	5,305 (48.5)	119,121 (37.6)	33,519 (38.9)	18,123 (48.0)	95,935 (40.0)	28,319 (44.0)	9,147 (51.5)	13,437 (38.8)	5,520 (44.2)	2,722 (46.0)
Biweekly period of test												
14 Dec 2020 to 27 Dec 2020	13 (0.0)	0 (0.0)	0 (0.0)	105 (0.0)	0 (0.0)	0 (0.0)	276 (0.1)	0 (0.0)	0 (0.0)	11 (0.0)	≤6 (≤0.0)	≤6 (≤0.0)
28 Dec 2020 to 10 Jan 2021	253 (0.2)	13 (0.0)	0 (0.0)	577 (0.2)	10 (0.0)	0 (0.0)	1,127 (0.5)	77 (0.1)	0 (0.0)	19 (0.1)	≤6 (≤0.0)	≤6 (≤0.0)
11 Jan 2021 to 24 Jan 2021	765 (0.5)	129 (0.3)	0 (0.0)	1,648 (0.5)	99 (0.1)	0 (0.0)	1,332 (0.6)	190 (0.3)	0 (0.0)	65 (0.2)	13 (0.1)	≤6 (≤0.0)
25 Jan 2021 to 7 Feb 2021	916 (0.6)	161 (0.4)	0 (0.0)	2,057 (0.6)	133 (0.2)	0 (0.0)	1,190 (0.5)	202 (0.3)	0 (0.0)	96 (0.3)	37 (0.3)	≤6 (≤0.0)

Supplemental Table S6: Baseline characteristics by vaccine product in Ontario, Quebec, British Columbia, and Manitoba

8 Feb 2021 to 21 Feb 2021	766 (0.5)	209 (0.5)	0 (0.0)	2,378 (0.8)	288 (0.3)	0 (0.0)	2,818 (1.2)	547 (0.8)	1 (0.0)	74 (0.2)	58 (0.5)	≤6 (≤0.0)
22 Feb 2021 to 7 Mar 2021	1,088 (0.7)	300 (0.7)	0 (0.0)	2,949 (0.9)	381 (0.4)	0 (0.0)	2,124 (0.9)	547 (0.8)	0 (0.0)	104 (0.3)	71 (0.6)	≤6 (≤0.0)
8 Mar 2021 to 21 Mar 2021	2,107 (1.4)	361 (0.8)	64 (0.6)	4,028 (1.3)	541 (0.6)	294 (0.8)	2,821 (1.2)	567 (0.9)	0 (0.0)	228 (0.7)	80 (0.6)	8 (0.1)
22 Mar 2021 to 4 Apr 2021	3,601 (2.4)	669 (1.6)	413 (3.8)	6,552 (2.1)	1,125 (1.3)	783 (2.1)	4,191 (1.7)	560 (0.9)	18 (0.1)	327 (0.9)	122 (1.0)	84 (1.4)
5 Apr 2021 to 18 Apr 2021	6,532 (4.3)	1,298 (3.0)	882 (8.1)	11,084 (3.5)	2,021 (2.3)	1,615 (4.3)	5,726 (2.4)	1,209 (1.9)	416 (2.3)	755 (2.2)	249 (2.0)	148 (2.5)
19 Apr 2021 to 2 May 2021	8,122 (5.4)	2,090 (4.9)	1,729 (15.8)	14,240 (4.5)	3,919 (4.5)	3,592 (9.5)	9,602 (4.0)	1,999 (3.1)	1,349 (7.6)	1,357 (3.9)	581 (4.7)	536 (9.1)
3 May 2021 to 16 May 2021	9,075 (6.0)	2,371 (5.5)	1,787 (16.3)	18,118 (5.7)	5,421 (6.3)	3,945 (10.4)	11,731 (4.9)	2,867 (4.5)	2,607 (14.7)	1,787 (5.2)	861 (6.9)	642 (10.9)
17 May 2021 to 30 May 2021	8,148 (5.4)	2,170 (5.0)	1,104 (10.1)	18,764 (5.9)	5,167 (6.0)	2,700 (7.1)	12,649 (5.3)	3,159 (4.9)	3,120 (17.6)	2,743 (7.9)	1,173 (9.4)	574 (9.7)
31 May 2021 to 13 Jun 2021	7,965 (5.3)	2,274 (5.3)	812 (7.4)	20,841 (6.6)	5,918 (6.9)	2,298 (6.1)	14,167 (5.9)	3,406 (5.3)	2,123 (12.0)	2,389 (6.9)	1,022 (8.2)	409 (6.9)
14 Jun 2021 to 27 Jun 2021	8,142 (5.4)	2,204 (5.1)	781 (7.1)	27,305 (8.6)	7,533 (8.7)	2,947 (7.8)	14,118 (5.9)	3,371 (5.2)	1,651 (9.3)	2,020 (5.8)	750 (6.0)	311 (5.3)
28 Jun 2021 to 11 Jul 2021	6,546 (4.3)	1,849 (4.3)	323 (3.0)	24,582 (7.8)	6,772 (7.9)	2,588 (6.8)	12,633 (5.3)	2,858 (4.4)	1,272 (7.2)	1,541 (4.5)	627 (5.0)	197 (3.3)
12 Jul 2021 to 25 Jul 2021	7,698 (5.1)	2,391 (5.6)	334 (3.1)	19,374 (6.1)	5,431 (6.3)	2,050 (5.4)	9,402 (3.9)	2,342 (3.6)	523 (2.9)	1,678 (4.8)	683 (5.5)	212 (3.6)
26 Jul 2021 to 8 Aug 2021	11,460 (7.6)	3,549 (8.3)	416 (3.8)	18,722 (5.9)	5,372 (6.2)	2,141 (5.7)	10,302 (4.3)	2,761 (4.3)	391 (2.2)	2,273 (6.6)	801 (6.4)	279 (4.7)
9 Aug 2021 to 22 Aug 2021	15,455 (10.2)	4,783 (11.1)	566 (5.2)	20,743 (6.6)	6,008 (7.0)	2,342 (6.2)	14,397 (6.0)	3,962 (6.2)	504 (2.8)	3,059 (8.8)	948 (7.6)	417 (7.0)
23 Aug 2021 to 5 Sep 2021	16,507 (10.9)	4,954 (11.5)	574 (5.2)	26,475 (8.4)	7,642 (8.9)	2,892 (7.7)	21,949 (9.1)	6,653 (10.3)	767 (4.3)	4,139 (12.0)	1,322 (10.6)	573 (9.7)
6 Sep 2021 to 19 Sep 2021	17,119 (11.3)	5,470 (12.7)	589 (5.4)	38,270 (12.1)	11,257 (13.1)	3,873 (10.2)	28,633 (11.9)	8,824 (13.7)	991 (5.6)	4,813 (13.9)	1,470 (11.8)	751 (12.7)
20 Sep 2021 to 30 Sep 2021	18,808 (12.4)	5,749 (13.4)	566 (5.2)	37,723 (11.9)	11,139 (12.9)	3,726 (9.9)	58,855 (24.5)	18,266 (28.4)	2,015 (11.4)	5,144 (14.9)	1,612 (12.9)	775 (13.1)
Number of tests in previous 3 months												
0	105,902 (70.1)	30,594 (71.2)	8,534 (78.0)	231,000 (73.0)	65,585 (76.1)	30,648 (81.1)	184,903 (77.0)	51,341 (79.8)	14,330 (80.7)	25,980 (75.0)	9,286 (74.4)	4,294 (72.6)
1	28,878 (19.1)	8,414 (19.6)	1,931 (17.7)	55,916 (17.7)	15,274 (17.7)	5,546 (14.7)	38,667 (16.1)	9,664 (15.0)	2,696 (15.2)	7,113 (20.5)	2,594 (20.8)	1,339 (22.6)

≥2	16,306	3,986 (9.3)	475 (4.3)	29,619	5,318 (6.2)	1,592 (4.2)	16,473	3,362 (5.2)	722 (4.1)	1,529 (4.4)	600 (4.8)	283 (4.8)
4 1.1. h	(10.8)	20 722	6 120	(9.4)	20, 100	17.004	(6.9)	26.296	7.075	12.044	5.950	2 000
Any comorbidity ^b	74,856	20,733	6,420	111,580	29,409	17,306	105,466	26,286	7,275	13,844	5,250	2,999
D : (60010	(49.5)	(48.2)	(58.7)	(35.3)	(34.1)	(45.8)	(43.9)	(40.8)	(41.0)	(40.0)	(42.1)	(50.7)
Receipt of 2019-	60,439	14,658	6,239	108,470	24,762	14,110	N/A	N/A	N/A	19,685	5,619	3,917
2020 and/or 2020- 2021 influenza	(40.0)	(34.1)	(57.0)	(34.3)	(28.7)	(37.3)				(56.9)	(45.0)	(66.2)
vaccination												
Neighbourhood												
income quintile ^c	24.025	8.407	1 512	52 200	15,323	5 0 1 9 (15 7)	28,543	9,634	4,294	4,630	3,547	(55 (11 1)
1 (lowest)	24,925 (16.5)	8,496 (19.8)	1,513 (13.8)	52,306 (16.5)	(17.8)	5,918 (15.7)		9,634 (15.0)	4,294 (24.2)	· · · · · · · · · · · · · · · · · · ·	3,547 (28.4)	655 (11.1)
2	29,058	8,344		60,760	16,358	6,937 (18.4)	(11.9)	12,518		(13.4)	2,815	1,032
2	(19.2)	8,344 (19.4)	1,912 (17.5)	(19.2)	(19.0)	0,937 (18.4)	40,477	(19.4)	4,220 (23.8)	6,070 (17.5)	(22.6)	,
3	31,201	8,831	2,050	65,083	17,081	7,835 (20.7)	(16.9) 45,915	12,257	3,288	7,212	2,018	(17.4) 1,163
3	(20.7)	(20.5)	(18.7)	(20.6)	(19.8)	7,855 (20.7)	43,913 (19.1)	(19.0)	5,288 (18.5)	(20.8)	(16.2)	(19.7)
4	32,293	8,542	2,226	68,137	17,913	8,174 (21.6)	55,061	12,825	2,709	7,089	1,996	1,252
4	(21.4)	8,542 (19.9)	(20.3)	(21.5)	(20.8)	8,174 (21.6)	(22.9)	(19.9)	(15.3)	(20.5)	(16.0)	(21.2)
5(1-1-1)		· · ·			. ,	8.022 (22.0)	· · ·	. ,			. ,	
5 (highest)	33,001 (21.8)	8,581 (20.0)	3,213 (29.4)	70,249 (22.2)	19,502 (22.6)	8,922 (23.6)	49,446 (20.6)	10,963 (17.0)	2,014 (11.3)	7,908 (22.8)	1,746 (14.0)	1,561 (26.4)
T. T 1												
Unknown/missing	608 (0.4)	200 (0.5)	26 (0.2)	-	-	-	20,601 (8.6)	6,170 (9.6)	1,223 (6.9)	1,713 (4.9)	358 (2.9)	253 (4.3)
Essential workers quintile ^d												
1 (0%-32.5%)	29,176	6,975	2,981	79,678	18,980	9,373 (24.8)	28,100	6,350 (9.9)	2,291	6,124	4,519	1,215
	(19.3)	(16.2)	(27.2)	(25.2)	(22.0)		(11.7)		(12.9)	(17.7)	(36.2)	(20.5)
2 (32.5%-42.3%)	36,412	9,741	2,577	73,680	19,649	8,680 (23.0)	47,340	10,689	3,744	8,720	2,249	1,608
	(24.1)	(22.7)	(23.6)	(23.3)	(22.8)		(19.7)	(16.6)	(21.1)	(25.2)	(18.0)	(27.2)
3 (42.3%-49.8%)	31,748	9,320	2,125	63,372	17,913	7,484 (19.8)	44,474	10,758	3,146	7,008	1,841	1,134
	(21.0)	(21.7)	(19.4)	(20.0)	(20.8)		(18.5)	(16.7)	(17.7)	(20.2)	(14.8)	(19.2)
4 (50.0%-57.5%)	28,457	8,890	1,817	54,441	15,440	6,376 (16.9)	37,449	10,799	2,585	6,668	1,926	1,051
	(18.8)	(20.7)	(16.6)	(17.2)	(17.9)		(15.6)	(16.8)	(14.6)	(19.3)	(15.4)	(17.8)
5 (57.5%-100%)	24,417	7,707	1,408	45,364	14,195	5,873 (15.5)	31,525	10,940	2,228	5,576	1,701	S
	(16.2)	(17.9)	(12.9)	(14.3)	(16.5)		(13.1)	(17.0)	(12.6)	(16.1)	(13.6)	
Unknown/missing	876 (0.6)	361 (0.8)	32 (0.3)	-	-	-	51,155		1,4831	17 (0.0)	130 (1.0)	≤6 (≤0.1)
Dorsons por							(21.3)		(23.0)			
Persons per												
dwelling quintile ^e	25.010	7 (25	1.074	62 105	16 250	7 502 (20.1)	50 120	14.094	2.126	0 770	2.026	1 401
1 (0–2.1)	25,910	7,635	1,974	63,105	16,356	7,593 (20.1)	52,139	14,984	3,126	8,770	2,926	1,481
	(17.1)	(17.8)	(18.0)	(19.9)	(19.0)		(21.7)	(23.3)	(17.6)	(25.3)	(23.4)	(25.0)

		0									
25,042	7,891	1,859	47,085	13,184	5,892 (15.6)	39,467	13,809	2,285	5,549	1,933	1,068
(16.6)	(18.4)	(17.0)	(14.9)	(15.3)		(16.4)	(21.5)	(12.9)	(16.0)	(15.5)	(18.1)
18,749	5,286	1,527	53,579	15,825	6,660 (17.6)	43,367	11,104	2,878	6,013	1,729	1,042
(12.4)	(12.3)	(14.0)	(16.9)	(18.4)		(18.1)	(17.3)	(16.2)	(17.4)	(13.9)	(17.6)
36,653	9,683	2,825	78,052	21,501	9,519 (25.2)	45,389	9,808	3,959	7,977	1,834	1,410
(24.3)	(22.5)	(25.8)	(24.7)	(24.9)		(18.9)	(15.2)	(22.3)	(23.0)	(14.7)	(23.8)
43,798	12,123	2,722	74,714	19,311	8,122 (21.5)	51,428	11,440	4,898	5,787	3,814	S
(29.0)	(28.2)	(24.9)	(23.6)	(22.4)		(21.4)	(17.8)	(27.6)	(16.7)	(30.6)	
934 (0.6)	376 (0.9)	33 (0.3)	-	-	-	8,253 (3.4)	3,222 (5.0)	602 (3.4)	17 (0.0)	130 (1.0)	≤6 (≤0.1)
21,763	9,003	1,316	69,145	23,454	9,774 (25.9)	26,250	11948	1004 (5.7)	3,227 (9.3)	4,116	683 (11.5)
(14.4)	(20.9)	(12.0)	(21.8)	(27.2)		(10.9)	(18.6)			(33.0)	
25,841	7,853	1,883	46,787	13,945	6,334 (16.8)	42,342	12,551	2,264	5,889	3,042	1,223
(17.1)	(18.3)	(17.2)	(14.8)	(16.2)		(17.6)	(19.5)	(12.8)	(17.0)	(24.4)	(20.7)
27,528	6,988	2,450	71,599	18,986	9,414 (24.9)	50,965	11,798	4,221	7,481	2,046	1,419
(18.2)	(16.3)	(22.4)	(22.6)	(22.0)		(21.2)	(18.3)	(23.8)	(21.6)	(16.4)	(24.0)
32,008	7,955	2,760	70,264	16,054	7,702 (20.4)	57,748	12,917	5,456	8,471	1,703	1,372
(21.2)	(18.5)	(25.2)	(22.2)	(18.6)		(24.1)	(20.1)	(30.7)	(24.5)	(13.6)	(23.2)
43,070	10,834	2,501	58,740	13,738	4,562 (12.1)	54,723	12,050	4,232	9,028	1,329	S
(28.5)	(25.2)	(22.9)	(18.6)	(15.9)		(22.8)	(18.7)	(23.8)	(26.1)	(10.6)	
876 (0.6)	361 (0.8)	30 (0.3)	-	-	-	8,015 (3.3)	3,103 (4.8)	571 (3.2)	17 (0.0)	130 (1.0)	≤6 (≤0.1)
	(16.6) 18,749 (12.4) 36,653 (24.3) 43,798 (29.0) 934 (0.6) 21,763 (14.4) 25,841 (17.1) 27,528 (18.2) 32,008 (21.2) 43,070 (28.5)	$\begin{array}{c cccc} (16.6) & (18.4) \\ \hline 18,749 & 5,286 \\ (12.4) & (12.3) \\ \hline 36,653 & 9,683 \\ (24.3) & (22.5) \\ \hline 43,798 & 12,123 \\ (29.0) & (28.2) \\ \hline 934 (0.6) & 376 (0.9) \\ \hline \\ \hline \\ 21,763 & 9,003 \\ (14.4) & (20.9) \\ \hline \\ 25,841 & 7,853 \\ (17.1) & (18.3) \\ \hline \\ 27,528 & 6,988 \\ (18.2) & (16.3) \\ \hline \\ 32,008 & 7,955 \\ (21.2) & (18.5) \\ \hline \\ 43,070 & 10,834 \\ (28.5) & (25.2) \\ \hline \end{array}$	$\begin{array}{c cccccc} (16.6) & (18.4) & (17.0) \\ \hline 18,749 & 5,286 & 1,527 \\ (12.4) & (12.3) & (14.0) \\ \hline 36,653 & 9,683 & 2,825 \\ (24.3) & (22.5) & (25.8) \\ \hline 43,798 & 12,123 & 2,722 \\ (29.0) & (28.2) & (24.9) \\ \hline 934 (0.6) & 376 (0.9) & 33 (0.3) \\ \hline \\ 21,763 & 9,003 & 1,316 \\ (14.4) & (20.9) & (12.0) \\ \hline \\ 25,841 & 7,853 & 1,883 \\ (17.1) & (18.3) & (17.2) \\ \hline \\ 27,528 & 6,988 & 2,450 \\ (18.2) & (16.3) & (22.4) \\ \hline \\ 32,008 & 7,955 & 2,760 \\ (21.2) & (18.5) & (25.2) \\ \hline \\ 43,070 & 10,834 & 2,501 \\ (28.5) & (25.2) & (22.9) \\ \hline \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$

S = suppressed; counts are suppressed because they are either small cell counts (≤ 6 , which cannot be disclosed because of privacy and data obligations) or they could be derived using other estimates in this table. ^aProportion reported, unless stated otherwise.

^bComorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

"Neighbourhood income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income. Material deprivation index quintile used in British Columbia; quintile 1 represents 'most deprived' and quintile 5 represents 'least deprived'.

^dPercentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision. "Range of persons per dwelling."

Percentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

		Hospitaliza	ition			Death		
	Test-positive vaccinated cases / total test- positive cases	Test-negative vaccinated controls, vaccinated / total test-negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)	Test-positive vaccinated cases / total test- positive cases	Test-negative vaccinated controls, vaccinated / total test-negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)
Ontario								
≥14 days after dose 1	1,289 / 15,265	60,443 / 36,8117	53 (50-56)	82 (81-83)	267 / 2,947	61,465 / 380,435	48 (41–54)	79 (76–82)
≥7 days after dose 2	270 / 14,246	148,552 / 456,226	96 (95–96)	98 (98–98)	58 / 2,738	148,764 / 467,734	95 (94–96)	97 (95–97)
Quebec								
≥14 days after dose 1	465 / 6,673	169,766 / 676,662	78 (75–80)	87 (85–88)	108 / 1,419	169,766 / 676,662	75 (70-80)	89 (86–92)
≥7 days after dose 2	164 / 6,372	217,206 / 724,102	94 (93–95)	99 (99–100)	23 / 1,334	217,206 / 724,102	96 (94–97)	100 (99–100)
British Columbia								
≥14 days after dose 1	520 / 5,092	108,127 / 630,534	45 (40-50)	76 (73–78)	95 / 681	108,127 / 630,534	22 (3-37)	69 (60–76)
≥7 days after dose 2	221 / 4,793	197,161 / 719,568	87 (85-89)	98 (97–98)	34 / 620	197,161 / 719,568	85 (78-89)	97 (96–98)
Manitoba								
≥14 days after dose 1	168 / 1,955	12,616 / 78,272	51 (43–58)	85 (82-87)	24 / 294	12,760 / 79,933	54 (30-70)	89 (83–93)
\geq 7 days after dose 2	58 / 1,845	25,051 / 90,707	92 (89–93)	97 (96–98)	9 / 279	25,100 / 92,273	91 (83–96)	97 (94–99)
Pooled								
≥14 days after dose 1	2,442 / 28,985	350,952 / 1,753,585	59 (39–73)	83 (78–87)	494 / 5341	352,118 / 1,767,564	54 (25-71)	83 (72–90)
\geq 7 days after dose 2	713 / 27,256	587,970 / 1,990,603	93 (88–96)	98 (96–99)	124 / 4971	588,231 / 2,003,677	93 (87–96)	98 (95–99)

Supplemental Table S7: Province-specific and pooled vaccine effectiveness ≥14 days after a first dose and ≥7 days after receiving a second dose against hospitalization and death in Ontario, Quebec, British Columbia, and Manitoba

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data. Supplemental Table S8: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death for mRNA and ChAdOx1 vaccines in Ontario, Quebec, British Columbia, and Manitoba

	mRNA vacci	ines (BNT162b2/	mRNA-1273)		ChAdOx1 vaccines (AstraZeneca Vaxzevria/COVISHIELD)					
Interval from vaccine dose to index date	Test-positive vaccinated cases / total test- positive cases	Test-negative vaccinated controls, vaccinated / total test- negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)	Interval from vaccine dose to index date	Test- positive vaccinated cases / total test- positive cases	Test-negative vaccinated controls, vaccinated / total test- negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)	
Ontario										
Dose 1					Dose 1					
0–13 days	1,116 / 15,694	16,346 / 323,418	-44 (-53 to - 35)	27 (22–32)	0-13 days	97 / 14,675	1,845 / 308,917	-11 (-36 to 10)	49 (37–59)	
14–27 days	540 / 151,18	17,591 / 324,663	35 (29–41)	74 (71–76)	14-27 days	65 / 14,643	1,833 / 308,905	25 (4-42)	73 (65–79)	
28–55 days	442 / 15,020	23,100 / 330,172	60 (56–63)	86 (84–87)	28-55 days	35 / 14,613	2,455 / 309,527	70 (58–78)	91 (88–94)	
56–83 days	166 / 14,744	10,070 / 317,142	65 (59–70)	89 (87–91)	≥56 days	16 / 14,594	1,279 / 308,351	74 (57–84)	93 (88–96)	
≥84 days	66 / 14,644	4,074 / 311,146	66 (56–73)	86 (81–89)						
Dose 2					Dose 2					
0–6 days	31 / 14,609	5,325 / 312,397	88 (83–91)	92 (88–94)	0-6 days	Suppressed	60 / 307,132	65 (-153 to 95)	90 (22–99)	
7–55 days	104 / 14,682	56,989 / 364,061	96 (95–97)	98 (97–98)	7-55 days	Suppressed	1017 / 308,089	88 (72–94)	94 (87–98)	
56–111 days	103 / 14,681	66,872 / 373,944	97 (96–97)	99 (98–99)	≥56 days	14 / 14592	2217 / 309,289	87 (77–92)	96 (94–98)	
≥112 days	50 / 14,628	12,729 / 319,801	92 (89–94)	96 (95–97)						
Quebec										
Dose 1					Dose 1					
0–13 days	339 / 7,153	35,354 / 542,250	29 (20–36)	50 (44–56)	0-13 days	40 / 6,854	4,518 / 511,414	34 (10–52)	37 (14–55)	
14–27 days	159 / 6,973	37,508 / 544,404	68 (63–73)	81 (78–84)	14-27 days	22 / 6,836	3,877 / 510,773	58 (36–72)	68 (52–80)	
28–55 days	152 / 6,966	66,573 / 573,469	83 (80–86)	89 (86–90)	28-55 days	18 / 6,832	5,422 / 512,318	75 (61–84)	85 (76–91)	
56–83 days	88 / 6,902	35,244 / 542,140	81 (77–85)	90 (88–92)	≥56 days	8 / 6,822	4,253 / 511,149	86 (72–93)	94 (87–97)	
≥84 days	38 / 6,852	16,889 / 523,785	83 (77–88)	95 (93–97)						
Dose 2		· · · · · · · · · · · · · · · · · · ·			Dose 2					

0–6 days	8 / 6,822	11,704 /	95 (90–97)	98 (95–99)	0-6 days	1 / 6,815	261 / 507,157	71 (-103 to 96)	84 (-18 to 98)
		518,600							
7–55 days	51 / 6,865	100,440 / 607,336	96 (95–97)	99 (99–99)	7-55 days	0 / 6,814	2,675 / 509,571	Not reliably estimable	Not reliably estimable
56–111 days	87 / 6,901	88,104 /	93 (91–94)	100 (100-100)	≥56 days	12 / 6,826	4,175 /	79 (62–88)	99 (99–100)
j-		595,000		,		/ 0,0_0	511,071	., (,	
\geq 112 days	11 / 6,825	9,932 /	92 (85–95)	99 (99–100)			, , , , , , , , , , , , , , , , , , ,		
-		516,828							
British Columbia					Dose 1				
Dose 1									
0–13 days	351 / 5,094	30,697 / 55,3104	-26 (-40 to - 13)	30 (21–37)	0-13 days	34 / 4,777	3,441 / 525,848	-9 (-53 to 22)	14 (-21 to 39)
14-27 days	163 / 4,906	29,428 /	39 (29–48)	71 (65–75)	14-27 days	19 / 4,762	3,115 /	33 (-6 to 57)	55 (28–71)
		551,835					525,522		
28–55 days	181 / 4,924	42,624 /	53 (46-60)	79 (76-82)	28-55 days	7 / 4,750	4,381 /	82 (63–92)	89 (77–95)
-		565,031					526,788		
56–83 days	93 / 4,836	18,845 /	46 (33–56)	80 (75-84)	≥56 days	4 / 4,747	1,894 /	77 (38–91)	87 (64–95)
		541,252					524,301		
\geq 84 days	81 / 4,824	7,840 / 530,247	-14 (-42 to 9)	68 (60–75)					
Dose 2					Dose 2				
0–6 days	18 / 4,761	8,075 / 530,482	75 (61–85)	89 (83–93)	0-6 days	0 / 4,743	180 / 522,587	_ ^b	_b
7–55 days	64 / 4,807	84,263 / 606,670	92 (89–93)	98 (97–98)	7-55 days	3 / 4,746	1,777 / 524,184	81 (42–94)	92 (75–97)
56–111 days	124 / 4,867	82,976 / 605,383	84 (80–86)	98 (97–98)	≥56 days	12 / 4,755	4,397 / 526,804	70 (47–83)	94 (90–97)
\geq 112 days	29 / 4,772	13,586 / 535,993	76 (66–84)	96 (95–98)			010,001		
Manitoba									
Dose 1	_				Dose 1				
0–13 days	89 / 1,944	4,365 / 69,953	28 (11-42)	61 (51–69)	0-13 days	12 / 1867	659 /66247	36 (-14 to 64)	39 (-10 to 66)
14–27 days	49 / 1,904	4,435 / 70,023	61 (48–71)	84 (78–88)	14-27 days	6 / 1861	592/66180	64 (20-84)	78 (50–90)
28–55 days	56 / 1,911	4,733 / 70,321	58 (45-68)	88 (85–91)	28-55 days	17 / 1872	914 /66502	34 (-6 to 59)	72 (55–83)
56–83 days	24 / 1,879	1,214 / 66,802	30 (-5 to 53)	87 (80–91)	≥56 days	13 / 1868	422 /66010	-9 (-90 to 37)	70 (46–83)
≥84 days	Suppressed / 1,860	304 / 65,892	42 (-41 to 76)	87 (67–95)					
Dose 2					Dose 2				
0–6 days	7 / 1,862	1,232 / 66,820	80 (58–90)	93 (86–97)	0-6 days	Suppressed / 1,855	11 / 65,599	No cases	No cases
7–55 days	37 / 1,892	10,919 / 76,507	88 (83–91)	95 (93–96)	7-55 days	Suppressed / 1,855	74 / 65,662	No cases	No cases

56–111 days	19 / 1,874	15,375 / 80,963	96 (93–97)	98 (97–99)	≥56 days	Suppressed / 1,856	189 /65,777	81 (-34 to 97)	89 (18–98)
≥112 days	8 / 1,863	4,229 / 69,817	93 (87–97)	98 (97–99)					
Pooled									
Dose 1					Dose 1				
0–13 days	1,895 / 29,885	86,762 / 1,488,725	1 (-42 to 31)	43 (25–57)	0-13 days	183 / 28,173	10,463 / 1,412,426	12 (-18 to 34)	37 (20–51)
14-27 days	911 / 28,901	88,962 / 1,490,925	53 (33–67)	78 (71–83)	14-27 days	112 / 28,102	9,417 / 1,411,380	43 (20–59)	69 (60–76)
28–55 days	831 / 28,821	137,030 / 1,538,993	66 (46–79)	86 (81–89)	28-55 days	77 / 28,067	13,172 / 1,415,135	69 (47–81)	86 (77–92)
56-83 days	371 / 28,361	65,373 / 1,467,336	61 (31–78)	87 (82–91)	≥56 days	41 / 28,031	7,848 / 1,409,811	68 (22–87)	88 (75–94)
≥84 days	>185 / 28,180	29,107 / 1,431,070	56 (0-81)	87 (71–94)					
Dose 2					Dose 2				
0–6 days	64 / 28,054	26,336 / 1,428,299	87 (74–93)	93 (88–96)	0-6 days	>1 / >13413	512 / 1,402,475	68 (-24 to 92)	87 (48–97)
7–55 days	256 / 28,246	252,611 / 1,654,574	94 (89–96)	98 (95–99)	7-55 days	>3 / >13415	5,543 / 1,407,506	86 (73–92)	94 (88–97)
56–111 days	333 / 28,323	253,327 / 1,655,290	94 (87–97)	99 (97–99)	≥56 days	>38 / 28,029	10,978 / 1,412,941	80 (69–87)	97 (91–99)
≥112 days	98 / 28,088	40,476 / 1,442,439	90 (81–94)	98 (96–99)					

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data.

^bVE estimated as 100% based on zero vaccinated test-positive cases.

Supplemental Table S9: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death \geq 14 days after a first dose (for subjects who received only 1 dose) and \geq 7 days after receiving a second dose by subject characteristics in Ontario, Quebec, British Columbia, and Manitoba

	Test-positive vaccinated cases / total test-positive cases	Test-negative vaccinated controls, vaccinated / total test-negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)
Ontario				
Age group				
18-59 years				
≥14 days after dose 1	211 / 6,926	42,102 / 300,262	81 (78–83)	89 (88–91)
\geq 7 days after dose 2	62 / 6,777	117,241 / 375,401	98 (97–98)	99 (98–99)
60-69 years				
≥14 days after dose 1	227 / 3,123	8,871 / 36,468	76 (72–79)	89 (87–90)
≥7 days after dose 2	54 / 2,950	15,913 / 43,510	97 (96–98)	98 (97–98)
70–79 years				
≥14 days after dose 1	341 / 2,844	5,645 / 19,328	67 (63–71)	80 (77-83)
\geq 7 days after dose 2	56 / 2,559	8,970 / 22,653	97 (96–97)	97 (96–98)
≥80 years				
≥14 days after dose 1	551 / 3,015	3,784 / 11,416	55 (50–59)	65 (59–70)
\geq 7 days after dose 2	111/2,575	6,415 / 14,047	95 (93–96)	94 (92–95)
Sex				
Females				
≥14 days after dose 1	597 / 7,051	36,152 / 207,591	56 (52-60)	84 (83–86)
\geq 7 days after dose 2	131 / 6,585	90,655 / 262,094	96 (95–97)	98 (98–98)
Males		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		x (
≥14 days after dose 1	733 / 8,857	24,250 / 159,883	50 (46–53)	81 (80-83)
\geq 7 days after dose 2	152 / 8,276	57,884 / 193,517	96 (95–96)	98 (97–98)
Presence of any	1027 0,270	01,0017 100,017	/0 (/0 /0)	
comorbidity				
Yes				
≥ 14 days after dose 1	1,220 / 12,061	31,840 / 168,492	52 (49–55)	80 (78-81)
\geq 7 days after dose 2	254 / 11,095	68,926 / 205,578	95 (95–96)	97 (97–98)
No	2547 11,055	00,7207 203,370	,5 (,5 ,6)	<i>ут (ут уб)</i>
≥ 14 days after dose 1	110 / 3,847	28,562 / 198,982	82 (79–85)	92 (90–93)
\geq 7 days after dose 2	29 / 3,766	79,613 / 250,033	98 (98–99)	99 (99–99)
<u>Ouebec</u>	2)73,700	79,0137 230,033)8()8–)))))())–)))
Age group				
18–59 years				
≥ 14 days after dose 1	58 / 2,807	116,676 / 525,777	93 (90–94)	94 (93–96)
\geq 14 days after dose 1 \geq 7 days after dose 2	40 / 2,789	149,114 / 558,215	96 (95–97)	100 (99–100)
$\frac{27}{60-69}$ years	4072,789	149,114 / 558,215	90 (93-97)	100 (99–100)
≥14 days after dose 1	95 / 1 401	24 606 / 82 220	85 (81-88)	89 (86–92)
	85 / 1,421	24,606 / 83,330	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
\geq 7 days after dose 2	31 / 1,367	34,679 / 93,403	96 (94–97)	100 (99–100)
70–79 years ^b	155 / 1 4/1	10 110 / 45 020	92 (70, 95)	96 (92, 90)
\geq 14 days after dose 1	155 / 1,461	18,112 / 45,860	82 (79–85) 96 (95–97)	86 (82–89) 100 (99–100)
\geq 7 days after dose 2	41 / 1,347	22,471 / 50,219	96 (95–97)	100 (99–100)
≥80 years	197 / 1 (10	10 272 / 21 605	06 (02 00)	94 (70. 07)
\geq 14 days after dose 1	187 / 1,610	10,372 / 21,695	86 (83-88)	84 (79–87)
\geq 7 days after dose 2	55 / 1,478	10,942 / 22,265	96 (95–97)	99 (98–99)
Sex				
Females	105/01/5	105 664 / 402 021	01 (70, 0.1)	00 (00 . 00)
≥ 14 days after dose 1	195/3,167	105,664 / 403,931	81 (79–84)	90 (88–92)
\geq 7 days after dose 2	70 / 3,042	131,065 / 429,332	95 (93–96)	100 (99–100)
Males	200 / 1 122	(1100 / 200 001	75 (72 - 70)	0.6.(0.1.00)
\geq 14 days after dose 1	290 / 4,132	64,102 / 272,731	75 (72–78)	86 (84-88)
\geq 7 days after dose 2	97 / 3,939	86,141 / 294,770	94 (93–95)	99 (99–100)
Presence of any				
comorbidity				
Yes				
\geq 14 days after dose 1	418 / 4,846	62,020 / 207,204	78 (76–80)	85 (83–87)
\geq 7 days after dose 2	136 / 4,564	77,763 / 222,947	94 (93–95)	99 (99–99)
No				
≥14 days after dose 1	67 / 2,453	107,746 / 469,458	91 (88–93)	94 (92–95)
\geq 7 days after dose 2	31 / 2,417	139,443 / 501,155	97 (95–98)	100 (100, 100)

British Columbia				
Age group				
18–59 years				
≥14 days after dose 1	140 / 2,550	73,013 / 500,757	66 (60–71)	79 (75–82)
\geq 7 days after dose 2	49 / 2,459	139,843 / 567,587	94 (92–95)	98 (98–99)
60-69 years				
≥14 days after dose 1	104 / 1,094	14,348 / 66,674	62 (53–69)	78 (72–83)
\geq 7 days after dose 2	49 / 1,039	26,174 / 78,500	90 (87–93)	98 (97–98)
70–79 years				
\geq 14 days after dose 1	132 / 905	11,527 / 39,063	59 (51–66)	75 (68–80)
\geq 7 days after dose 2	61 / 834	18,634 / 46,170	88 (85–91)	98 (97–98)
≥80 years	172 (742	0.000 / 0.1.0.40	52 (42, 50)	(0. (61. 75)
≥ 14 days after dose 1	172 / 742	9,239 / 24,040	52 (43–59)	69 (61–75)
\geq 7 days after dose 2	75 / 645	12,510 / 27,311	84 (80–88)	94 (92–96)
Sex Females		+ +		
≥ 14 days after dose 1	224 / 2,257	6,332 / 282,650	52 (45–58)	78 (74–81)
\geq 14 days after dose 1 \geq 7 days after dose 2	93 / 2,126	115,220 / 391,538	89 (86–91)	98 (97–98)
Males	9372,120	113,2207 391,338	89 (80-91)	98 (97-98)
\geq 14 days after dose 1	324 / 3,034	44,795 / 290,884	34 (26–41)	73 (70–77)
\geq 7 days after dose 2	141 / 2,851	81,941 / 328,030	84 (81–87)	97 (97–98)
Presence of any	111/2,001	01,7117520,050		21 (21 20)
comorbidity				
Yes				
≥14 days after dose 1	465 / 3,441	49,921 / 226,338	45 (39–50)	70 (67–73)
\geq 7 days after dose 2	206/3,182	82,686 / 259,103	85 (83-87)	97 (96–97)
No				
≥14 days after dose 1	83 / 1,850	58,206 / 404,196	72 (65–78)	85 (82–88)
\geq 7 days after dose 2	28 / 1,795	114,475 / 460,465	95 (93–97)	99 (98–99)
Manitoba				
Age group				
18–59 years				
\geq 14 days after dose 1	62 / 1,218	8,823 / 63,818	67 (57–74)	86 (82-89)
\geq 7 days after dose 2	24 / 1,180	26,497 / 81,492	96 (94–97)	98 (96–98)
60–69 years	20 / 22 /	2.001./7.005	50 (40, 51)	0.6 (70, 00)
\geq 14 days after dose 1	<u>39 / 326</u> 19 / 306	2,001 / 7,985	59 (43–71)	86 (78–90)
\geq 7 days after dose 2 70–79 years	19/300	3,809 / 9,793	90 (83–93)	96 (93–98)
≥ 14 days after dose 1	37 / 278	1,228 / 4,230	62 (47–74)	90 (84–94)
\geq 7 days after dose 2	9 / 250	2,057 / 5,059	95 (89–97)	99 (97–99)
≥ 80 years)7230	2,0377 3,037)) (0)–)1)	<u> </u>
≥ 14 days after dose 1	32 / 203	571 / 2,178	47 (22–64)	73 (54–84)
\geq 7 days after dose 2	16 / 187	1,343 / 2,950	89 (81–93)	95 (90–97)
Sex				
Females				
≥14 days after dose 1	83 / 1,102	7,255 / 43,584	59 (49–67)	87 (83–90)
≥7 days after dose 2	34 / 1,053	20,206 / 56,535	94 (92–96)	98 (96–98)
Males				
≥14 days after dose 1	87 / 923	5,368 / 34,627	43 (29–55)	83 (78–87)
\geq 7 days after dose 2	34 / 870	13,500 / 42,759	91 (88–94)	97 (95–98)
Presence of any				
comorbidity		+		
Yes	142/1202	5.025./20.772	50 (41 50)	04/00.07
\geq 14 days after dose 1	143 / 1,303	5,925 / 29,773	50 (41–58)	84 (80-87)
\geq 7 days after dose 2	56 / 1,216	13,372 / 37,220	91 (89–93)	96 (95–97)
No ≥14 days after dose 1	27 / 722	6,698 / 48,438	76 (64–84)	90 (86–94)
\geq 14 days after dose 1 \geq 7 days after dose 2	12 / 707	20,334 / 62,074	96 (94–98)	90 (86–94) 98 (97–99)
Pooled	12/10/	20,3347 02,074	JU (J T -70)	70 (77-77)
Age group				
18–59 years		+		
≥ 14 days after dose 1	471 / 13,501	240,614 / 139,0614	80 (60–90)	88 (80–93)
\geq 7 days after dose 2	175 / 13,205	432,695 / 1,582,695	96 (94–98)	99 (98–99)
2		- , , - , - , - , - , - , - , - ,	>	
60–69 years				
≥14 days after dose 1	455 / 5,964	49,826 / 194,457	73 (57–82)	86 (80–90)

70–79 years				
≥ 14 days after dose 1	665 / 5,488	36,512 / 108,481	69 (56–79)	83 (76–88)
\geq 7 days after dose 2	167 / 4,990	52,132 / 124,101	95 (90–97)	99 (97–99)
≥80 years	,			
≥14 days after dose 1	942 / 5,570	23,966 / 59,329	64 (35-81)	73 (62–81)
\geq 7 days after dose 2	257 / 4,885	31,210 / 66,573	92 (86–96)	96 (92–98)
Sex				
Females				
≥14 days after dose 1	1,099 / 13,577	155,403 / 937,756	64 (45–77)	85 (80-89)
≥7 days after dose 2	328 / 12,806	357,146 / 1,139,499	94 (91–96)	99 (97–99)
Males				
≥14 days after dose 1	1,434 / 16,946	138,515 / 758,125	54 (29–70)	81 (76-86)
≥7 days after dose 2	424 / 15,936	239,466 / 859,076	92 (87–95)	98 (96–99)
Presence of any comorbidity				
Yes				
≥14 days after dose 1	2,246 / 21,651	149,706 / 631,807	59 (37–73)	80 (73-85)
\geq 7 days after dose 2	652 / 20,057	242,747 / 724,848	92 (87–95)	98 (95–99)
No				
≥14 days after dose 1	287 / 8,872	201,212 / 1,121,074	82 (71-89)	91 (87–94)
\geq 7 days after dose 2	100 / 8,685	353,865 / 1,273,727	97 (95–98)	99 (98–100)

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data.

^bModel adjusted for sex, biweekly period of test, presence of any comorbidity that increase the risk of severe COVID-19, number of SARS-CoV-2 tests in previous 3 months, and receipt of influenza vaccination in current or prior influenza season.

Supplemental Table S10: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death \geq 14 days after a first dose (for subjects who received only 1 dose) and \geq 7 days after receiving a second dose by vaccine product in Ontario, Quebec, British Columbia, and Manitoba

	Test-positive vaccinated cases / total test-positive cases	Test-negative vaccinated controls, vaccinated / total test-negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)
Ontario				
BNT162b2				
≥14 days after dose 1	1,044 / 15,622	43,712 / 350,784	50 (46–53)	82 (81–84)
\geq 7 days after dose 2	201 / 14,779	89,149 / 396,221	95 (95–96)	98 (97–98)
mRNA-1273				
≥14 days after dose 1	170 / 14,748	11,123 / 318,195	68 (63–72)	85 (82–87)
\geq 7 days after dose 2	44 / 14,622	26,496 / 333,568	97 (95–97)	98 (97–99)
BNT162b2/mRNA-1273				
\geq 14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	Suppressed	20,945 / 328,017	99 (98–99)	99 (98–99)
ChAdOx1		5.5.55 (010 - 500	56 (18, 61)	
\geq 14 days after dose 1	116 / 14,694	5,567 / 312,639	56 (47–64)	86 (83-89)
\geq 7 days after dose 2	20 / 14,598	3,234 / 310,306	87 (80–92)	96 (94–97)
ChAdOx1/mRNA mixed				
schedule	NT / A	NI/A	NT/A	NT / A
\geq 14 days after dose 1	N/A 6 / 14,584	N/A 8,715 / 315,787	N/A 99 (97–99)	N/A 99 (98–100)
\geq 7 days after dose 2	0 / 14,584	8,/15/315,/8/	99 (97–99)	99 (98–100)
Quebec				
BNT162b2 ≥14 days after dose 1	375 / 7,189	123,899 / 630,795	77 (75–80)	87 (86–89)
\geq 14 days after dose 1 \geq 7 days after dose 2		123,8997 630,795		
\geq / days after dose 2 mRNA-1273	116 / 6,930	151,606 / 658,502	94 (93–95)	100 (99–100)
≥ 14 days after dose 1	(2) (()7(22 215 / 520 211	96 (92, 90)	02 (00, 04)
\geq 14 days after dose 1 \geq 7 days after dose 2	62 / 6,876 26 / 6,840	<u>32,315 / 539,211</u> 41,389 / 548,285	86 (82–89) 95 (93–97)	92 (90–94) 100 (99–100)
BNT162b2/mRNA-1273	2070,840	41,3897 348,283	95 (93-97)	100 (99–100)
≥ 14 days after dose 1	N/A	N/A		
\geq 14 days after dose 1 \geq 7 days after dose 2	7 / 6,821	5,481 / 512,377	91 (80–95)	99 (98–100)
≥/ days after dose 2 ChAdOx1	// 0,821	3,481/312,377	91 (80–93)	99 (98–100)
≥ 14 days after dose 1	48 / 6,862	12 552 / 520 449	74 (65, 80)	95 (70, 90)
\geq 14 days after dose 1 \geq 7 days after dose 2	48 / 6,802	<u>13,552 / 520,448</u> 6,850 / 513,746	74 (65–80) 87 (77–93)	85 (79–89) 99 (99–100)
ChAdOx1/mRNA mixed	12/0,820	0,8307 313,740	87 (77-93)	99 (99–100)
schedule				
≥ 14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	6 / 6,820	11,880 / 518,776	96 (92–98)	100 (99–100)
British Columbia	070,820	11,8807 518,770	90 (92-98)	100 (99–100)
BNT162b2				
≥ 14 days after dose 1	426 / 5,169	77,202 / 599,609	39 (33–45)	74 (71–77)
\geq 7 days after dose 2	164 / 4,907	132,386 / 654,793	86 (84–88)	97 (97–98)
mRNA-1273	10474,907	152,5807 054,795	00 (04-00)	97 (97-98)
≥ 14 days after dose 1	92 / 4,835	21,535 / 543,942	53 (42–62)	82 (78–85)
\geq 14 days after dose 1 \geq 7 days after dose 2	34 / 4.777	33.990 / 556.397	89 (85–92)	98 (97–99)
BNT162b2/mRNA-1273	5474,777	33,7707 330,377	87 (85-72)	<i>98()1–99</i>
>14 days after dose 1	N/A	N/A	N/A	N/A
\geq 14 days after dose 1 \geq 7 days after dose 2	217 / 4,960	180,825 / 703,232	87 (85–88)	98 (97–98)
ChAdOx1	21// 4,700	100,0237 703,232	07 (05-00)	70 (77-70)
≥ 14 days after dose 1	30 / 4,773	9,390/ 531,797	65 (50–75)	78 (68–84)
\geq 7 days after dose 2	15 / 4,758	6,174 / 528,581	73 (56–84)	94 (90–96)
ChAdOx1/mRNA mixed	15 / 1,750	0,1717 520,501	15 (50 04)	21(20/20)
schedule				
≥14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	0 / 4.743	1,658 / 524,065	_b	_b
Manitoba		-,		
BNT162b2				
≥ 14 days after dose 1	102 / 1,957	7,510 / 73,098	52 (41-61)	84 (80-87)
\geq 7 days after dose 2	30 / 1,885	17,380 / 82,968	94 (91–96)	97 (96–98)
mRNA-1273	20, 1,000	1,,2007 02,700		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
≥ 14 days after dose 1	32 / 1,887	3,176 / 68,764	64 (49–75)	91 (87–94)
	28 / 1,883	7,407 / 72,995	87 (81–91)	97 (96–98)

BNT162b2/mRNA-1273				
≥14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	6 / 1,861	5,736 / 71,324	96 (92–98)	97 (93–99)
ChAdOx1				
≥14 days after dose 1	36 / 1,891	1,928 / 67,516	34 (8–53)	73 (61–81)
\geq 7 days after dose 2	Suppressed / 1,856	263 / 65,851	87 (4–98)	93 (46–99)
ChAdOx1/mRNA mixed schedule				
≥14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	Suppressed / 1,858	2,917 / 68,505	96 (89–99)	98 (93–99)
Pooled				
BNT162b2				
≥14 days after dose 1	1,947 / 29,937	252,323 / 1,654,286	57 (34–72)	83 (77–87)
\geq 7 days after dose 2	511 / 28,501	390,521 / 1,792,484	93 (89–96)	98 (96–99)
mRNA-1273				
≥14 days after dose 1	356 / 28,346	68,149 / 1,470,112	70 (51-82)	88 (82–92)
\geq 7 days after dose 2	132 / 28,122	109,282 / 1,511,245	93 (87–96)	99 (97–99)
BNT162b2/mRNA-1273				
≥14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	>230/>13,642	212,987 / 1,614,950	95 (86–98)	98 (97–99)
ChAdOx1				
≥14 days after dose 1	230 / 35,034	30,437 / 1,939,296	60 (41–72)	81 (74–87)
\geq 7 days after dose 2	>39 / 34,844	13,376 / 1,922,235	84 (75–89)	97 (91–99)
ChAdOx1/mRNA mixed schedule				
≥14 days after dose 1	N/A	N/A	N/A	N/A
\geq 7 days after dose 2	>12 / 28,005	25,170 / 1,427,133	97 (95–99)	99 (98–100)

N/A-not applicable

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data.

^bVE estimated as 100% based on zero vaccinated test-positive cases.

Supplemental Table S11: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death ≥14 days after a first dose (for subjects who received only 1 dose) and ≥7 days after receiving a second dose by SARS-CoV-2 lineage in Ontario, Quebec, British Columbia, and Manitoba

	Test-positive vaccinated cases / total test-positive cases	Test-negative vaccinated controls, vaccinated / total test-negative controls	Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)	
Ontario					
Non-VOC					
≥14 days after dose 1	40 / 5,190	60,402 / 367,474	96 (95–97)	71 (59–79)	
≥7 days after dose 2	Suppressed	148,539 / 455,611	_ ^b	95 (87–98)	
Alpha (B.1.1.7)					
≥14 days after dose 1	741 / 6,242	60,402 / 367,474	32 (26–37)	83 (81–84)	
\geq 7 days after dose 2	33 / 5,534	148,539 / 455,611	99 (98–99)	96 (95–97)	
Beta/Gamma (B.1.3.51 or P.1)					
≥14 days after dose 1	28 / 194	60,402 / 367,474	14 (-28 to 43)	83 (73-89)	
≥7 days after dose 2	Suppressed	148,539 / 455,611	98 (90–99)	96 (82–99)	
Beta (B.1.351)	~~PF				
≥14 days after dose 1	15 / 153	60,402 / 367,474	45 (6-68)	62 (30–79)	
\geq 7 days after dose 2	Suppressed	148,539 / 455,611	99 (89–100)	95 (61–99)	
Gamma (P.1)	Suppressed	140,3577 455,011	<i>уу</i> (0) 100)	75 (01 77)	
≥ 14 days after dose 1	36 / 338	60,402 / 367,474	39 (14–57)	80 (71-87)	
\geq 7 days after dose 2	Suppressed	148,539 / 455,611	99 (95–100)	94 (75–99)	
\geq 7 days after dose 2 Delta (B.1.617.2)	Suppressed	140,337 / 433,011	<i>77</i> (7J-100)	74 (1J-99)	
≥ 14 days after dose 1	181 / 1,464	60,402 / 367,474	28 (16–39)	85 (83-88)	
	,		· · · · · · · · · · · · · · · · · · ·		
\geq 7 days after dose 2	147 / 1,430	148,539 / 455,611	76 (72–80)	98 (98–99)	
Quebec					
Alpha (B.1.1.7) ^c	2.62 / 1.271	1.60 7.66 / 62.6 602	25 (25, 42)	0.6 (02, 00)	
≥14 days after dose 1	262 / 1,371	169,766 / 636,603	35 (26-43)	86 (83-88)	
\geq 7 days after dose 2	8 / 1,117	217,206 / 684,043	98 (97–99)	99 (98–100)	
Delta (B.1.617.2) ^d					
≥14 days after dose 1	25 / 463	13,516 / 20,620	97 (96–98)	97 (95–98)	
≥7 days after dose 2	94 / 532	179,476 / 186,580	99 (99–99)	_b	
British Columbia					
Non-VOC					
≥14 days after dose 1	38 / 489	108,127 / 630,534	59 (43–71)	17 (-22 to 44)	
≥7 days after dose 2	2 / 453	197,161 / 719,568	99 (95–100)	73 (-11 to 93)	
Alpha (B.1.1.7)					
≥14 days after dose 1	122 / 784	108,127 / 630,534	11 (-8 to 27)	79 (74–83)	
≥7 days after dose 2	4 / 666	197,161 / 249,401	98 (96–99)	97 (93–99)	
Beta/Gamma (B.1.3.51 or P.1)					
≥14 days after dose 1	12 / 202	108,127 / 630,534	69 (45–83)	79 (60–89)	
≥7 days after dose 2	0 / 190	197,161 / 719,568	_ ^b	_ ^b	
Beta (B.1.351)					
≥14 days after dose 1	2 / 5	108,127 / 630,534	_ ^e	_ ^e	
≥7 days after dose 2	0/3	197,161 / 719,568	_ ^b	_ ^b	
Gamma (P.1)					
≥14 days after dose 1	117 / 572	108,127 / 630,534	-24 (-52 to -1)	76 (69-81)	
\geq 7 days after dose 2	4 / 459	197,161 / 719,568	98 (94–99)	98 (93–99)	
Delta (B.1.617.2)					
≥14 days after dose 1	79 / 1,047	108,127 / 630,534	61 (50–69)	81 (77-85)	
\geq 7 days after dose 2	161 / 1,129	197,161 / 719,568	56 (48-63)	98 (97–98)	
Manitoba	7 -				
Non-VOC					
≥14 days after dose 1	36 / 939	12,623 / 78,211	79 (71–85)	84 (76-89)	
\geq 7 days after dose 2	31/934	33,706 / 99,294	93 (90–95)	94 (91–96)	
Alpha (B.1.1.7)	01/ /0T	55,1007 <i>)</i> ,2)7	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	/ /////////////////////////////////////	
≥ 14 days after dose 1	84 / 713	12,623 / 78,211	31 (13-45)	88 (85–91)	
\geq 7 days after dose 2	14 / 643	33,706 / 99,294	96 (93–97)	97 (94–98)	
Beta/Gamma (B.1.3.51 or P.1)	17/043	55,100/ 77,274	70 (93-97)	77 (74-70)	
≥ 14 days after dose 1	Suppressed / 18	12,623 / 78,211	_e	74 (4–93)	
\geq 14 days after dose 1 \geq 7 days after dose 2	Suppressed / 18	33,706 / 99,294			
2	Suppressed / 15	55,700799,294	No cases	No cases	
Beta (B.1.351)	C 1/0	10 (02 / 79 011	_e	_e	
\geq 14 days after dose 1 \geq 7 days after dose 2	Suppressed / 8 Suppressed	12,623 / 78,211 33,706 / 99,294	-e No cases	-° No cases	

Gamma (P.1)					
≥14 days after dose 1	Suppressed / 10	12,623 / 78,211	_e	73 (-79 to 96)	
≥7 days after dose 2	Suppressed / 8	33,706 / 99,294	No cases	No cases	
Delta (B.1.617.2)					
≥14 days after dose 1	8 / 94	12,623 / 78,211	52 (0-77)	86 (70–94)	
≥7 days after dose 2	9 / 95	33,706 / 99,294	80 (60–90)	99 (97–99)	
Pooled					
Non-VOC					
≥14 days after dose 1	114 / 6618	181,152 / 1,076,219	85 (42–96)	66 (14-86)	
≥7 days after dose 2	>33 / >1387	230,867 / 818,862	99 (91–100)	92 (83–97)	
Alpha (B.1.1.7)					
≥14 days after dose 1	1209 / 9110	350,918 / 1,712,822	2 29 (19–37)	84 (80-88)	
≥7 days after dose 2	59 / 7960	596,612 / 1,488,349	98 (96–99)	98 (96–99)	
Beta/Gamma (B.1.3.51 or P.1)					
≥14 days after dose 1	>40 / 414	181,152 / 1,076,219	_ ^e	81 (74–87)	
≥7 days after dose 2	_f	_ ^f	_f	_f	
Beta (B.1.351)					
≥14 days after dose 1	>17 / 166	181,152 / 1,076,219	_1	61 (32–78)	
≥7 days after dose 2	_f	_ ^f	_f	_f	
Gamma (P.1)					
≥14 days after dose 1	>153 / 920	181,152 / 1,076,219	8 (-65 to 48)	77 (72–81)	
≥7 days after dose 2	>4 / >467	230,867 / 818,862	98 (96–99)	97 (93–99)	
Delta (B.1.617.2)					
≥14 days after dose 1	293 / 3068	194,668 / 1,096,839	75 (-5 to 94)	89 (77–95)	
≥7 days after dose 2	411 / 3186	558,882 / 1,461,053	88 (34–98)	99 (97–99)	

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data.

^bVE estimated as 100% based on zero vaccinated test-positive cases.

^cAnalysis period restricted from 28 December 2020 to 30 September 2021.

^dAnalysis period restricted from 26 July 2021 to 30 September 2021.

^eVE not reported due to extremely imprecise 95% confidence intervals.

^fNot applicable as VE estimate from only one province available.

Supplemental Table S12: Province-specific and pooled vaccine effectiveness against severe outcomes of hospitalization or death by varying dosing intervals among subjects who received 2 doses of an mRNA in Ontario, Quebec, British Columbia, and Manitoba

Interval between doses	vaccinated cases / total test-positive cases		Unadjusted vaccine effectiveness (95% CI)	Adjusted ^a vaccine effectiveness (95% CI)	
Ontario	1	1	I	r	
0-6 days after dose 2					
21-34 days	14 / 14,592	1,323 / 308,395	78 (62–87)	85 (74–91)	
35–55 days	Suppressed	1,654 / 308,726	94 (85–97)	93 (84–97)	
56–83 days	6 / 14,584	1,454 / 308,526	91 (81–96)	96 (90–98)	
≥84 days	6 / 14,584	873 / 307,945	86 (68–94)	92 (82–96)	
7–55 days after dose 2					
21–34 days	44 / 14,622	7,892 / 314,964	88 (84–91)	94 (92–96)	
35–55 days	11 / 14,589	20,983 / 328,055	99 (98–99)	99 (98–99)	
56–83 days	32 / 14,610	20,457 / 327,529	97 (95–98)	98 (97–99)	
≥84 days	17 / 14,595	7,575 / 314,647	95 (92–97)	98 (97–99)	
56-111 days after dose 2					
21–34 days	22 / 14,600	7,922 / 314,994	94 (91–96)	98 (96–98)	
35–55 days	11 / 14,589	25,707 / 332,779	99 (98–100)	99 (98–99)	
56–83 days	48 / 14,626	24,173 / 331,245	96 (94–97)	99 (98–99)	
≥84 days	21 / 14,599	8,987 / 316,059	95 (92–97)	98 (98–99)	
≥112 days after dose 2					
21–34 days	36 / 14,614	6,599 / 313,671	89 (84–92)	96 (95–97)	
35–55 days	8 / 14,586	3,709 / 310,781	95 (91–98)	97 (93–98)	
56–83 days	Suppressed	1,424 / 308,496	94 (84–98)	97 (91–99)	
≥84 days	Suppressed	830 / 307,902	97 (82–100)	98 (85-100)	
Quebec	-				
0-6 days after dose 2					
21–34 days	1 / 6,815	930 / 507,826	92 (43–99)	99 (90–100)	
35–55 days	1 / 6,815	1,483 / 508,379	95 (64–99)	97 (78–100)	
56–83 days	4 / 6,818	5,290 / 512,186	94 (85–98)	94 (85–98)	
≥84 days	2 / 6,816	3,990 / 510,886	96 (85–99)	99 (95–100)	
7–55 days after dose 2					
21–34 days	9 / 6,823	4,020 / 510,916	83 (68–91)	97 (95–99)	
35–55 days	2 / 6,816	12,446 / 519,342	99 (95–100)	100 (99–100)	
56–83 days	19 / 6,833	56,807 / 563,703	98 (96–98)	99 (99–100)	
≥84 days	21 / 6,835	27,126 / 534,022	94 (91–96)	99 (99–100)	
56-111 days after dose 2					
21–34 days	7 / 6,821	1,989 / 508,885	74 (45–88)	97 (93–98)	
35–55 days	8 / 6,822	11,875 / 518,771	95 (90–97)	99 (99–100)	
56–83 days	24 / 6,838	52,981 / 559,877	97 (95–98)	100 (100-100)	
≥84 days	48 / 6,862	21,225 / 528,121	83 (78–87)	100 (99–100)	
≥112 days after dose 2					
21–34 days	2 / 6,816	877 / 507,773	83 (32–96)	99 (96–100)	
35–55 days	0 / 6,814	531 / 507,427	Not estimable	Not estimable	
56–83 days	7 / 6,821	922 / 507,818	44 (-19 to 73)	98 (97–99)	
≥84 days	2 / 6,816	7,543 / 514,439	98 (92–100)	100 (99–100)	
British Columbia					
0-6 days after dose 2					
21-34 days	0 / 4,743	471 / 522,878	_b	_b	
35–55 days	3 / 4,746	2,291 / 524,698	86 (55–95)	90 (69–97)	
56–83 days	8 / 4,751	3,784 / 526,191	77 (53–88)	90 (79–95)	
≥84 days	7 / 4,750	1,527 / 523,934	50 (-6 to 76)	85 (67–93)	
7–55 days after dose 2					
21–34 days	6 / 4,749	2,045 / 524,452	68 (28-86)	91 (79–96)	
35–55 days	15 / 4,758	20,985 / 543,392	92 (87–95)	97 (94–98)	

56-83 days	16 / 4,759	49,941 / 572,348	96 (94–98)	99 (98–99)
\geq 84 days	27 / 4,770	11,262 / 533,669	74 (61–82)	95 (93–97)
56–111 days after dose 2			(******)	
21–34 days	1 / 4,744	1,242 / 523,649	91 (37–99)	97 (80-100)
35–55 days	3 / 4,746	16,993 / 539,400	98 (94–99)	100 (98–100)
56–83 days	62 / 4,805	48,252 / 570,659	86 (82–89)	98 (98–99)
\geq 84 days	58 / 4,801	16,452 / 538,859	61 (50–70)	96 (95–97)
≥112 days after dose 2				, , , , , , , , , , , , , , , , , , , ,
21–34 days	5 / 4,748	1,145 / 523,552	52 (-15 to 80)	91 (78–96)
35–55 days	16 / 4,759	7,860 / 530,267	78 (63–86)	96 (94–98)
56–83 days	6 / 4,749	1,468 / 523,875	55 (0-80)	96 (92–98)
≥84 days	2 / 4,745	3,053 / 525,460	93 (71–98)	99 (95–100)
Manitoba	· · ·			
0-6 days after dose 2				
21–34 days	Suppressed / 1,855	454 / 66,042	No cases	No cases
35–55 days	Suppressed / 1,860	436 / 66,024	59 (2-83)	87 (68–95)
56–83 days	Suppressed / 1,856	285 / 65,873	88 (12–98)	97 (79–100)
\geq 84 days	Suppressed / 1,856	45 / 65,633	_c	84 (-17 to 98)
7–55 days after dose 2				
$\frac{21-34 \text{ days}}{21-34 \text{ days}}$	14 / 1,869	3,345 / 68,933	85 (75–91)	93 (88–96)
35–55 days	12 / 1,867	4,140 / 69,728	90 (82–94)	94 (90–97)
56–83 days	8 / 1,863	3,054 / 68,642	91 (81–95)	97 (93–98)
\geq 84 days	Suppressed / 1,858	343 / 65,931	69 (4–90)	94 (81–98)
56–111 days after dose 2	,,	,,	• (• • • • •)	, (02 , 0)
21–34 days	Suppressed / 1,860	4,452 / 70,040	96 (90–98)	98 (96–99)
35–55 days	10 / 1,865	6,500 / 72,088	95 (90–97)	97 (95–99)
56–83 days	Suppressed / 1,859	4,099 / 69,687	97 (91–99)	99 (97–100)
≥84 days	Suppressed / 1,855	273 / 65,861	No cases	No cases
≥112 days after dose 2				
21–34 days	Suppressed / 1,860	3,226 / 68,814	95 (87–98)	98 (95–99)
35–55 days	Suppressed / 1,858	692 / 66,280	85 (52–95)	99 (95–100)
56–83 days	Suppressed / 1,855	132 / 65,720	No cases	No cases
≥84 days	Suppressed / 1,855	16 / 65,604	No cases	No cases
Pooled	,,,.,.,.,.,.,.,.,.,.,.,.,.,.,			
0–6 days after dose 2				
21–34 days	>15 / 28,005	3,178 / 1,405,141	79 (65–88)	94 (47–99)
35–55 days	>4 / >13,421	5,864 / 1,407,827	87 (66–95)	91 (85–95)
56–83 days	>18 / 28,009	10,813 / 1,412,776	89 (77–95)	94 (89–96)
\geq 84 days	>15 / 28,006	6,435 / 1,408,398	79 (28–94)	93 (79–97)
7–55 days after dose 2		.,,,		
21–34 days	73 / 28,063	17,302 / 1,419,265	84 (77–89)	94 (91–97)
35–55 days	40 / 28,030	58,554 / 1,460,517	97 (89–99)	98 (94–99)
56-83 days	75 / 28,065	130,259 / 1,532,222	96 (94–98)	99 (97–99)
\geq 84 days	>65 / 28,058	46,306 / 1,448,269	88 (70–96)	98 (94–99)
56–111 days after dose 2			(* * * *)	
21-34 days	>30 / 28,025	15,605 / 1,417,568	91 (79–97)	98 (97–98)
35–55 days	32 / 28,022	61,075 / 1,463,038	97 (94–99)	99 (98–100)
56-83 days	>134 / 28,128	129,505 / 1,531,468	95 (89–97)	99 (98–100)
\geq 84 days	>127 / 28,117	46,937 / 1,448,900	85 (52–95)	99 (95–100)
≥112 days after dose 2	, 12, , 20,117		00 (02 70)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21–34 days	>43 / 28,038	11,847 / 1,413,810	85 (64–94)	97 (93–99)
35–55 days	>24 / 28,017	12,792 / 1,414,755	88 (68–96)	97 (95–98)
56–83 days	>13 / >13,425	3,946 / 1,405,909	75 (-1 to 94)	97 (96–99)
20 02 augo	>4 / >13,416	11,442 / 1,413,405	97 (91–99)	99 (97–100)

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data.

^bVE estimated as 100% based on zero vaccinated test-positive cases.

^cVE not reported due to extremely imprecise 95% confidence intervals.

Outcome/subgroup	Heterogeneity,	Heterogeneity,		
	pooled unadjusted model	pooled adjusted model		
Hospitalization				
\geq 14 days after dose 1	$I^2 = 99\%, \ \tau^2 = 0.1655, \ p < 0.01$	$I^2 = 96\%, \tau^2 = 0.0660, p < 0.01$		
≥7 days after dose 2	$I^2 = 98\%$, $\tau^2 = 0.2413$, p < 0.01	$I^2 = 99\%, \tau^2 = 0.5800, p < 0.01$		
Death				
\geq 14 days after dose 1	$I^2 = 96\%, \ \tau^2 = 0.2252, \ p < 0.01$	$I^2 = 92\%, \tau^2 = 0.2379, p < 0.01$		
≥7 days after dose 2	$I^2 = 92\%$, $\tau^2 = 0.3546$, p < 0.01	$I^2 = 92\%, \tau^2 = 0.7433, p < 0.01$		
Severe outcomes (hospitalizatio	on or death)			
mRNA vaccines				
Dose 1				
0–13 days	$I^2 = 98\%, \tau^2 = 0.1310, p < 0.01$	$I^2 = 94\%, \tau^2 = 0.0772, p < 0.01$		
14–27 days	$I^2 = 96\%, \tau^2 = 0.1171, p < 0.01$	$I^2 = 88\%, \ \tau^2 = 0.0658, \ p < 0.01$		
28–55 days	$I^2 = 97\%, \ \tau^2 = 0.2124, \ p < 0.01$	$I^2 = 90\%, \tau^2 = 0.0669, p < 0.01$		
56–83 days	$I^2 = 95\%, \tau^2 = 0.3143, p < 0.01$	$I^2 = 89\%, \tau^2 = 0.1038, p < 0.01$		
≥84days	$I^2 = 97\%, \tau^2 = 0.6669, p < 0.01$	$I^2 = 97\%, \tau^2 = 0.6302, p < 0.01$		
Dose 2				
0–6 days	$I^2 = 81\%, \tau^2 = 0.3687, p < 0.01$	$I^2 = 76\%, \tau^2 = 0.2988, p < 0.01$		
7–55 days	$I^2 = 95\%, \tau^2 = 0.3107, p < 0.01$	$I^2 = 97\%, \tau^2 = 0.6757, p < 0.01$		
56–111 days	$I^2 = 98\%, \tau^2 = 0.5009, p < 0.01$	$I^2 = 98\%, \tau^2 = 0.6084, p < 0.01$		
≥112 days	$I^2 = 88\%, \tau^2 = 0.2864, p < 0.01$	$I^2 = 91\%, \tau^2 = 0.6390, p < 0.01$		
ChAdOx1 vaccine				
Dose 1				
0-13 days	$I^2 = 71\%$, $\tau^2 = 0.0603$, p = 0.02	$I^2 = 54\%, \tau^2 = 0.0325, p = 0.09$		
14-27 days	$I^2 = 60\%, \tau^2 = 0.0651, p = 0.06$	$I^2 = 31\%, \tau^2 = 0.0207, p = 0.22$		
28-55 days	$I^2 = 77\%, \tau^2 = 0.2198, p < 0.01$	$I^2 = 80\%, \tau^2 = 0.2015, p < 0.01$		
≥56 days	$I^2 = 88\%, \tau^2 = 0.7048, p < 0.01$	$I^2 = 83\%, \tau^2 = 0.4557, p < 0.01$		
Dose 2				
0-6 days	$I^2 = 0\%, \tau^2 = 0, p = 0.88$	$I^2 = 0\%, \tau^2 = 0, p = 0.75$		
7-55 days	$I^2 = 0\%, \tau^2 = 0, p = 0.57$	$I^2 = 0\%, \tau^2 = 0, p = 0.60$		
≥56 days	$I^2 = 33\%, \tau^2 = 0.0804, p = 0.21$	$I^2 = 88\%, \tau^2 = 0.8968, p < 0.01$		
Age group				
18–59 years				
≥14 days after dose 1	$I^2 = 97\%, \tau^2 = 0.4934, p < 0.01$	$I^2 = 96\%, \tau^2 = 0.2888, p < 0.01$		
\geq 7 days after dose 2	$I^2 = 92\%, \ \tau^2 = 0.2064, \ p < 0.01$	$I^2 = 94\%, \ \tau^2 = 0.4852, \ p < 0.01$		
60–69 years				
≥14 days after dose 1	$I^2 = 94\%, \tau^2 = 0.1928, p < 0.01$	$I^2 = 88\%, \tau^2 = 0.1008, p < 0.01$		
\geq 7 days after dose 2	$I^2 = 93\%, \tau^2 = 0.3422, p < 0.01$	$I^2 = 95\%, \tau^2 = 1.0229, p < 0.01$		
70–79 years				
≥14 days after dose 1	$I^2 = 94\%, \tau^2 = 0.1271, p < 0.01$	$I^2 = 85\%, \tau^2 = 0.1184, p < 0.01$		
\geq 7 days after dose 2	$I^2 = 94\%, \ \tau^2 = 0.3061, \ p < 0.01$	$I^2 = 94\%, \tau^2 = 0.7209, p < 0.01$		
≥80 years				
\geq 14 days after dose 1	$I^2 = 98\%, \tau^2 = 0.3697, p < 0.01$	$I^2 = 89\%, \tau^2 = 0.1080, p < 0.01$		
\geq 7 days after dose 2	$I^2 = 96\%, \tau^2 = 0.3839, p < 0.01$	$I^2 = 89\%, \tau^2 = 0.3947, p < 0.01$		
Sex	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,		
Females				
\geq 14 days after dose 1	$I^2 = 98\%, \tau^2 = 0.1888, p < 0.01$	$I^2 = 94\%, \tau^2 = 0.1044, p < 0.01$		
\geq 7 days after dose 2	$I^2 = 95\%, \tau^2 = 0.1877, p < 0.01$	$I^2 = 97\%, \tau^2 = 0.5889, p < 0.01$		
Males	,	····, ····, ·····		
≥ 14 days after dose 1	$I^2 = 98\%, \tau^2 = 0.1878, p < 0.01$	$I^2 = 93\%, \tau^2 = 0.0698, p < 0.01$		
\geq 7 days after dose 2	$I^2 = 98\%, \tau^2 = 0.2939, p < 0.01$	$I^2 = 98\%, \tau^2 = 0.7051, p < 0.01$		
Presence of any comorbidity	, voio, void void void void void void void void	,,,,,,,		

Supplemental Table S13: Test of heterogeneity for all pooled primary analyses

Yes		
	$l^2 = 0.00(-\tau^2 = 0.1757, \tau < 0.01)$	$l^2 = 0.60/(-r^2 = 0.0881)$ m < 0.01
\geq 14 days after dose 1	$I^2 = 99\%, \tau^2 = 0.1757, p < 0.01$	$I^2 = 96\%, \tau^2 = 0.0881, p < 0.01$
\geq 7 days after dose 2	$I^2 = 98\%, \tau^2 = 0.2575, p < 0.01$	$I^2 = 98\%, \tau^2 = 0.5554, p < 0.01$
No	$P_{2}^{2} = 0.40/2 = 0.2181 = \pm 0.01$	$r^2 = 0.00(-2) = 0.1264 = \pm 0.01$
≥ 14 days after dose 1	$I^2 = 94\%, \tau^2 = 0.2181, p < 0.01$	$I^2 = 90\%, \tau^2 = 0.1364, p < 0.01$
\geq 7 days after dose 2	$I^2 = 83\%, \tau^2 = 0.1745, p < 0.01$	$I^2 = 92\%, \ \tau^2 = 0.4905, \ p < 0.01$
Vaccine product		
BNT162b2	P 000/ 2 0 1001	P 0.69 2 0.0967
≥ 14 days after dose 1	$I^2 = 99\%, \tau^2 = 0.1901, p < 0.01$	$I^2 = 96\%, \tau^2 = 0.0867, p < 0.01$
\geq 7 days after dose 2	$I^2 = 97\%, \tau^2 = 0.2179, p < 0.01$	$I^2 = 98\%, \tau^2 = 0.6920, p < 0.01$
mRNA-1273	P 050/ 2 0 2477	P = 0.107 - 2 = 0.1569 = -0.01
≥ 14 days after dose 1	$I^2 = 95\%, \tau^2 = 0.2477, p < 0.01$	$I^2 = 91\%, \tau^2 = 0.1568, p < 0.01$
\geq 7 days after dose 2	$I^2 = 93\%, \tau^2 = 0.3952, p < 0.01$	$I^2 = 95\%, \tau^2 = 0.6847, p < 0.01$
BNT162b2/mRNA-1273		
≥ 14 days after dose 1	-	-
\geq 7 days after dose 2	$I^2 = 96\%, \tau^2 = 1.1175, p < 0.01$	$I^2 = 80\%, \tau^2 = 0.2465, p < 0.01$
ChAdOx1	12 940/ -2 0 1020 0 01	12 900/ -2 0.0922 0.01
\geq 14 days after dose 1	$I^2 = 84\%, \tau^2 = 0.1230, p < 0.01$	$I^2 = 80\%, \tau^2 = 0.0833, p < 0.01$
\geq 7 days after dose 2	$I^2 = 45\%$, $\tau^2 = 0.0934$, p = 0.14	$I^2 = 90\%, \ \tau^2 = 0.9094, \ p < 0.01$
ChAdOx1/mRNA mixed schedule		
\geq 14 days after dose 1	-	$I^2 = 62\%, \tau^2 = 0.3639, p = 0.07$
\geq 7 days after dose 2	$I^2 = 39\%, \tau^2 = 0.1377, p = 0.19$	$I^2 = 62\%, \tau^2 = 0.3639, p = 0.07$
SARS-CoV-2 lineage		
Non-VOC	$P = 0.00 + \frac{2}{2} + 1.4166 + 0.01$	<u>2</u> 050/ 2 0 (207
\geq 14 days after dose 1	$I^2 = 98\%, \tau^2 = 1.4166, p < 0.01$	$I^2 = 95\%, \tau^2 = 0.6307, p < 0.01$
\geq 7 days after dose 2	$I^2 = 97\%, \tau 2 = 3.0728, p < 0.01$	$I^2 = 58\%, \tau^2 = 0.3056, p = 0.09$
Alpha (B.1.1.7)	P = (10) = 2 = 0.0104 = 0.05	P 929/ -2 0.0401 0.01
\geq 14 days after dose 1	$I^2 = 61\%, \tau 2 = 0.0104, p = 0.05$	$I^2 = 82\%, \tau^2 = 0.0491, p < 0.01$
\geq 7 days after dose 2	$I^2 = 81\%, \tau 2 = 0.2803, p < 0.01$	$I^2 = 70\%, \tau^2 = 0.2549, p = 0.02$
Beta/Gamma (B.1.3.51 or P.1)	P = 950/(-2) - 0.6921 - 0.001	1^2 00/ $-^2$ 0 = 0.72
\geq 14 days after dose 1	$I^2 = 85\%, \tau 2 = 0.6831, p < 0.01$	$I^2 = 0\%, \tau^2 = 0, p = 0.73$
\geq 7 days after dose 2	-	-
Beta (B.1.351)	P = 720/(-2) = 0.8052 = -0.02	$V_{2}^{2} = 00^{1/2} - \frac{1}{2} = 0.02$
\geq 14 days after dose 1	$I^2 = 73\%, \tau 2 = 0.8952, p = 0.03$	$I^2 = 0\%, \tau^2 = 0, p = 0.93$
\geq 7 days after dose 2	-	-
Gamma (P.1)	$l^2 = 850/(-2) = 0.1785$ m < 0.01	$I^2 = 0\%, \tau^2 = 0, p = 0.67$
\geq 14 days after dose 1	$I^2 = 85\%, \tau 2 = 0.1785, p < 0.01$ $I^2 = 0\%, \tau^2 = 0, p = 0.53$	<i>,</i> ,1
\geq 7 days after dose 2	1 - 0%, t - 0, p = 0.35	$I^2 = 0\%, \tau^2 = 0, p = 0.32$
Delta (B.1.617.2)	$I^2 = 99\%, \tau^2 = 2.0504, p < 0.01$	$l^2 = 0.40$, $\tau^2 = 0.5761$ = < 0.01
\geq 14 days after dose 1 \geq 7 days after dose 2		$I^2 = 94\%, \tau^2 = 0.5761, p < 0.01$ $I^2 = 98\%, \tau^2 = 0.6445, p < 0.01$
\geq 7 days after dose 2	$I^2 = 100\%, \tau^2 = 3.1546, p < 0.01$	$1 - 98\%, t^2 = 0.0443, p < 0.01$
Interval between doses 0–6 days after dose 2		
	$I^2 = 2\%, \tau^2 = 0.0093, p = 0.31$	$I^2 = 8104$ $\tau^2 = 2.1665$ $\tau = 0.02$
21–34 days 35–55 days		$I^2 = 81\%, \tau^2 = 2.1665, p = 0.02$
55–55 days 56–83 days	$I^2 = 70\%, \tau^2 = 0.6279, p = 0.02$ $I^2 = 55\%, \tau^2 = 0.2817, p = 0.08$	$I^2 = 0\%, \tau^2 = 0, p = 0.51$ $I^2 = 10\%, \tau^2 = 0.0036, p = 0.20$
\geq 84 days	$I^2 = 55\%, \tau^2 = 0.2817, p = 0.08$ $I^2 = 70\%, \tau^2 = 1.2437, p < 0.01$	$I^2 = 19\%, \tau^2 = 0.0936, p = 0.29$ $I^2 = 70\%, \tau^2 = 0.8153, p = 0.02$
7–55 days after dose 2	$I^2 = 79\%, \tau^2 = 1.2437, p < 0.01$	$I^2 = 70\%, \tau^2 = 0.8153, p = 0.02$
	$I^2 = 5106$ $\tau^2 = 0.0677$ $r = 0.11$	$I^2 = 620/(\pi^2 = 0.1501)$ $r = 0.05$
21–34 days 35–55 days	$I^2 = 51\%, \tau^2 = 0.0677, p = 0.11$ $I^2 = 0.2\%, \tau^2 = 1.2703, p < 0.01$	$I^2 = 62\%, \tau^2 = 0.1501, p = 0.05$ $I^2 = 86\%, \tau^2 = 1.1650, p < 0.01$
55–55 days 56–83 days	$I^2 = 92\%, \tau^2 = 1.2793, p < 0.01$ $I^2 = 71\%, \tau^2 = 0.1895, p = 0.02$	$I^2 = 86\%, \tau^2 = 1.1650, p < 0.01$ $I^2 = 87\%, \tau^2 = 0.4281, p < 0.01$
-	$I^2 = 71\%, \tau^2 = 0.1895, p = 0.02$ $I^2 = 0.4\%, \tau^2 = 0.8531, p < 0.01$	$I^2 = 87\%, \tau^2 = 0.4281, p < 0.01$ $I^2 = 0.4\%, \tau^2 = 0.0583, p < 0.01$
≥84 days 56–111 days after dose 2	$I^2 = 94\%, \tau^2 = 0.8531, p < 0.01$	$I^2 = 94\%, \tau^2 = 0.9583, p < 0.01$
JU-111 uays alter uuse 2		

21–34 days	$I^2 = 80\%, \tau^2 = 0.6144, p < 0.01$	$I^2 = 0\%, \tau^2 = 0, p = 0.78$
35–55 days	$I^2 = 87\%, \tau^2 = 0.6703, p < 0.01$	$I^2 = 74\%, \tau^2 = 0.3732, p < 0.01$
56–83 days	$I^2 = 95\%, \tau^2 = 0.4620, p < 0.01$	$I^2 = 96\%, \tau^2 = 0.8032, p < 0.01$
≥84 days	$I^2 = 97\%, \tau^2 = 1.0410, p < 0.01$	$I^2 = 98\%, \tau^2 = 1.2924, p < 0.01$
≥112 days after dose 2		
21–34 days	$I^2 = 77\%, \tau^2 = 0.6388, p < 0.01$	$I^2 = 69\%, \tau^2 = 0.4948, p = 0.02$
35–55 days	$I^2 = 86\%, \tau^2 = 0.6369, p < 0.01$	$I^2 = 18\%, \tau^2 < 0.0001, p = 0.30$
56–83 days	$I^2 = 87\%, \tau 2 = 1.3047, p < 0.01$	$I^2 = 15\%$, $\tau^2 = 0.0482$, p = 0.31
≥84 days	$I^2 = 0\%$, $\tau^2 = 0.0606$, p = 0.39	$I^2 = 61\%, \tau^2 = 0.9336, p = 0.08$

Outcome/subgroup	Test-positive	Test-negative		Unadjusted model		Adjusted model ^a
	vaccinated cases / total test- positive cases	vaccinated controls, vaccinated / total test-negative controls	Vaccine effectiveness (95% CI)	Heterogeneity	Vaccine effectiveness (95% CI)	Heterogeneity
Hospitalization						
\geq 14 days after dose 1	2,799 / 33,924	351,068 / 1,753,334	59 (73-40)	$I^2 = 99\%, \tau^2 = 0.1620, p < 0.01$	83 (87–78)	$I^2 = 96\%, \tau^2 = 0.0658, p < 0.01$
≥7 days after dose 2	753 / 31,878	588,166 / 1,990,432	93 (96–88)	$I^2 = 99\%, \tau^2 = 0.3050, p < 0.01$	98 (99–96)	$I^2 = 99\%, \tau^2 = 0.6086, p < 0.01$
Death	-1	1	1		-	
≥14 days after dose 1	567 / 6,064	352,518 / 1,771,529	53 (71–24)	$I^2 = 96\%, \tau^2 = 0.2276, p < 0.01$	83 (90–71)	$I^2 = 93\%, \tau^2 = 0.2525, p < 0.01$
\geq 7 days after dose 2	144 / 5,641	588,447 / 2,007,458	93 (96-87)	$I^2 = 92\%$, $\tau^2 = 0.3302$, p < 0.01	98 (99–95)	$I^2 = 94\%, \tau^2 = 0.8657, p < 0.01$
Severe outcomes (hospitali	zation or death)					
mRNA vaccines						
Dose 1						
0–13 days	2,202 / 34,738	86,729 / 1,488,361	2 (31 to -40)	$I^2 = 98\%$, $\tau^2 = 0.1242$, p < 0.01	44 (57–26)	$I^2 = 94\%, \tau^2 = 0.0703, p < 0.01$
14–27 days	1,054 / 33,590	88,982 / 1,490,614	53 (66–34)	$I^2 = 96\%$, $\tau^2 = 0.1092$, p < 0.01	78 (83–71)	$I^2 = 88\%, \tau^2 = 0.0617, p < 0.01$
28–55 days	939 / 33,475	137,105 / 1,538,737	67 (79–47)	$I^2 = 97\%$, $\tau^2 = 0.2063$, p < 0.01	86 (89-82)	$I^2 = 90\%$, $\tau^2 = 0.0670$, p < 0.01
56–83 days	432 / 32,968	65,346 / 1,466,978	61 (77–31)	$I^2 = 95\%$, $\tau^2 = 0.3111$, p < 0.01	87 (90-82)	$I^2 = 88\%, \tau^2 = 0.0919, p < 0.01$
≥84days	198 / 32,739	29,104 / 1,430,736	57 (82–1)	$I^2 = 97\%, \tau^2 = 0.6837, p < 0.01$	86 (94–69)	$I^2 = 97\%, \tau^2 = 0.6443, p < 0.01$
Dose 2						
0–6 days	72 / 32,608	26,332 / 1,427,964	87 (93–74)	$I^2 = 82\%, \tau^2 = 0.3715, p < 0.01$	93 (96-88)	$I^2 = 77\%$, $\tau^2 = 0.3116$, p < 0.01
7–55 days	283 / 32,819	252,683 / 1,654,315	94 (97-89)	$I^2 = 95\%, \tau^2 = 0.3258, p < 0.01$	98 (99–95)	$I^2 = 97\%, \tau^2 = 0.7018, p < 0.01$
56–111 days	346 / 32,882	253,388 / 1,655,020	94 (97–87)	$I^2 = 98\%, \tau^2 = 0.5800, p < 0.01$	99 (99–97)	$I^2 = 98\%, \tau^2 = 0.6339, p < 0.01$
\geq 112 days	102 / 32,638	40,541 / 1,442,173	90 (95-82)	$I^2 = 91\%, \tau^2 = 0.3372, p < 0.01$	98 (99–95)	$I^2 = 92\%, \tau^2 = 0.7196, p < 0.01$
ChAdOx1 vaccine			• `` ´ ´ ´		· · · · ·	· · · · · · · · ·
Dose 1						
0-13 days	233 / 32,769	10,441 / 1,412,073	8 (36 to -31)	$I^2 = 83\%, \tau^2 = 0.1006, p < 0.01$	35 (45-23)	$I^2 = 15\%, \tau^2 = 0.0075, p = 0.32$
14-27 days	134 / 32,670	9,460 / 1,411,092	43 (59–20)	$I^2 = 62\%, \tau^2 = 0.0663, p = 0.05$	69 (76–60)	$I^2 = 35\%, \tau^2 = 0.0231, p = 0.20$
28-55 days	89 / 32,625	13,182 / 1,414,814	68 (81–47)	$I^2 = 77\%, \tau^2 = 0.2165, p < 0.01$	86 (91–77)	$I^2 = 80\%, \tau^2 = 0.1913, p < 0.01$
≥56 days	45 / 32,581	7,840 / 1,409,472	69 (87–23)	$I^2 = 89\%, \tau^2 = 0.7094, p < 0.01$	88 (94–75)	$I^2 = 83\%, \tau^2 = 0.4465, p < 0.01$
Dose 2	,				· · · · ·	
0-6 days	>1 / >13,413	511 / 1,402,143	56 (86 to - 34)	$I^2 = 0\%, \tau^2 = 0, p = 0.60$	82 (94–44)	$I^2 = 0\%, \tau^2 = 0, p = 0.92$
7-55 days	>3/>13,415	5,543 / 1,407,175	87 (93–76)	$I^2 = 0\%, \tau^2 = 0, p = 0.44$	93 (96-88)	$I^2 = 0\%, \tau^2 = 0, p = 0.65$
≥56 days	>38 / 32,575	10,957 / 1,412,589	81 (89–67)	$I^2 = 64\%, \tau^2 = 0.1949, p = 0.04$	97 (99–91)	$I^2 = 89\%, \tau^2 = 0.9065, p < 0.01$
Subject characteristics	•	• • • • •			/	
Age group						
18–59 years						
≥14 days after dose 1	528 / 16,089	240,726 / 1,390,441	80 (90-60)	$I^2 = 97\%, \tau^2 = 0.4977, p < 0.01$	89 (93-80)	$I^2 = 96\%, \tau^2 = 0.2915, p < 0.01$
\geq 7 days after dose 2	190 / 15,751	432,893 / 1,582,608	96 (98–94)	$I^2 = 94\%, \tau^2 = 0.2570, p < 0.01$	99 (99–97)	$I^2 = 94\%, \tau^2 = 0.4949, p < 0.01$
60–69 years	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , , ,	<i>,</i>		, , ,	
≥ 14 days after dose 1	541 / 6,916	49,857 / 194,472	72 (82–57)	$I^2 = 93\%$, $\tau^2 = 0.1889$, p < 0.01	86 (90-80)	$I^2 = 87\%, \tau^2 = 0.0936, p < 0.01$

Supplemental Table S14: Pooled vaccine effectiveness from the sensitivity analyses

	150 / 6 500	00 505 / 005 140	04 (07,00)	12 050/ 2 0 1000	00 (00 05)	12 0 601 2 1 0 2 0 0 1
\geq 7 days after dose 2	158 / 6,533	80,525 / 225,140	94 (97–89)	$I^2 = 95\%, \tau^2 = 0.4230, p < 0.01$	98 (99–96)	$I^2 = 96\%, \tau^2 = 1.0389, p < 0.01$
70–79 years						
\geq 14 days after dose 1	765 / 6,260	36,481 / 108,451	69 (79–55)	$I^2 = 94\%, \tau^2 = 0.1285, p < 0.01$	83 (88–76)	$I^2 = 86\%, \tau^2 = 0.1218, p < 0.01$
\geq 7 days after dose 2	178 / 5,673	52,158 / 124,128	95 (97–90)	$I^2 = 95\%, \tau^2 = 0.3267, p < 0.01$	99 (99–97)	$I^2 = 95\%, \tau^2 = 0.8140, p < 0.01$
≥80 years						
≥14 days after dose 1	765 / 6,260	36,481 / 108,451	64 (81–34)	$I^2 = 98\%, \tau^2 = 0.3725, p < 0.01$	73 (81–61)	$I^2 = 90\%, \tau^2 = 0.1220, p < 0.01$
\geq 7 days after dose 2	178 / 5,673	52,158 / 124,128	92 (96–86)	$I^2 = 96\%, \tau^2 = 0.3968, p < 0.01$	96 (98–92)	$I^2 = 91\%, \tau^2 = 0.4413, p < 0.01$
Sex						
Females						
≥14 days after dose 1	1,267 / 15,767	155,536 / 937,579	65 (77–46)	$I^2 = 97\%, \tau^2 = 0.1846, p < 0.01$	85 (89-80)	$I^2 = 94\%, \tau^2 = 0.1047, p < 0.01$
≥7 days after dose 2	352 / 14,852	357,374 / 1,139,417	94 (96–90)	$I^2 = 96\%, \tau^2 = 0.2250, p < 0.01$	98 (99–97)	$I^2 = 97\%, \tau^2 = 0.6326, p < 0.01$
Males						
≥14 days after dose 1	1,629 / 19,665	138,492 / 758,081	54 (70-30)	$I^2 = 98\%, \tau^2 = 0.1859, p < 0.01$	81 (86–76)	$I^2 = 93\%, \tau^2 = 0.0697, p < 0.01$
\geq 7 days after dose 2	447 / 18,483	239,427 / 859,016	92 (96-86)	$I^2 = 98\%, \tau^2 = 0.3486, p < 0.01$	98 (99–96)	$I^2 = 98\%, \tau^2 = 0.7320, p < 0.01$
Presence of any comorbidi	ity					
Yes						
≥14 days after dose 1	2,570 / 25,151	149,773 / 631,585	59 (73–38)	$I^2 = 99\%$, $\tau^2 = 0.1731$, p < 0.01	80 (85–73)	$I^2 = 96\%, \tau^2 = 0.0880, p < 0.01$
\geq 7 days after dose 2	694 / 23,275	242,901 / 724,713	93 (96-87)	$I^2 = 98\%$, $\tau^2 = 0.2964$, p < 0.01	98 (99–95)	$I^2 = 98\%, \tau^2 = 0.5856, p < 0.01$
No						
≥14 days after dose 1	326 / 10,281	201,255 / 1,121,075	82 (89–71)	$I^2 = 94\%, \tau^2 = 0.2178, p < 0.01$	91 (94–87)	$I^2 = 90\%, \tau^2 = 0.1335, p < 0.01$
≥7 days after dose 2	105 / 10,060	353,900 / 1,273,720	97 (98–95)	$I^2 = 88\%, \tau^2 = 0.2499, p < 0.01$	99 (100–98)	$I^2 = 92\%$, $\tau^2 = 0.5062$, p < 0.01
Vaccine product						
BNT162b2						
\geq 14 days after dose 1	2,215 / 34,751	252,380 / 1,654,012	58 (73-35)	$I^2 = 99\%, \tau^2 = 0.1855, p < 0.01$	83 (87–77)	$I^2 = 96\%, \tau^2 = 0.0865, p < 0.01$
\geq 7 days after dose 2	534 / 33,070	390,671 / 1,792,303	93 (96–89)	$I^2 = 98\%, \tau^2 = 0.2676, p < 0.01$	98 (99–96)	$I^2 = 99\%$, $\tau^2 = 0.7192$, p < 0.01
mRNA-1273						
≥14 days after dose 1	413 / 32,949	68,157 / 1,469,789	70 (82–51)	$I^2 = 95\%$, $\tau^2 = 0.2484$, p < 0.01	88 (92-82)	$I^2 = 92\%, \tau^2 = 0.1694, p < 0.01$
\geq 7 days after dose 2	152 / 32,688	109,328 / 1,510,960	93 (96-87)	$I^2 = 93\%$, $\tau^2 = 0.3531$, p < 0.01	98 (99–96)	$I^2 = 96\%, \ \tau^2 = 0.7751, \ p < 0.01$
BNT162b2/mRNA-1273						
≥14 days after dose 1	-	-	-	-	-	-
≥7 days after dose 2	230 / 13,642	212,989 / 1,614,621	95 (99-85)	$I^2 = 97\%$, $\tau^2 = 1.3097$, p < 0.01	98 (99–97)	$I^2 = 78\%, \tau^2 = 0.2082, p < 0.01$
ChAdOx1						
\geq 14 days after dose 1	268 / 39,618	30,482 / 1,939,010	60 (72–41)	$I^2 = 84\%, \tau^2 = 0.1227, p < 0.01$	81 (86–75)	$I^2 = 80\%, \tau^2 = 0.0771, p < 0.01$
≥7 days after dose 2	19 / 20,246	13,355 / 1,921,883	85 (91–75)	$I^2 = 64\%, \tau^2 = 0.1585, p = 0.04$	97 (99–91)	$I^2 = 91\%, \tau^2 = 0.9271, p < 0.01$
ChAdOx1/mRNA mixed sc	hedule	•	· · · ·	· · · · · · · ·	,	· · · · · ·
\geq 14 days after dose 1	-	-	-	-	-	-
\geq 7 days after dose 2	6 / 13,421	25,182 / 1,426,814	97 (99–95)	$I^2 = 47\%, \tau^2 = 0.1633, p = 0.15$	99 (100–98)	$I^2 = 67\%, \tau^2 = 0.3962, p = 0.05$
SARS-CoV-2 lineage	· · ·	· · · · ·	· · · ·	· · · · ·		· · · ·
Non-VOC						
\geq 14 days after dose 1	125 / 8,290	181,262 / 1,075,998	85 (96-41)	$I^2 = 99\%$, $\tau^2 = 1.4743$, p < 0.01	66 (86–14)	$I^2 = 95\%$, $\tau^2 = 0.6239$, p < 0.01
\geq 7 days after dose 2	33 / 1,387	230,867 / 818,862	99 (100–91)	$I^2 = 97\%$, $\tau^2 = 3.0144$, p < 0.01	92 (96-84)	$I^2 = 57\%, \tau^2 = 0.2131, p = 0.10$
Alpha (B.1.1.7)		. , , ,		· · · · ·	/	• • • •
≥14 days after dose 1	1,372 / 11,171	351,028 / 1,712,601	30 (40–19)	$I^2 = 77\%, \tau^2 = 0.0189, p < 0.01$	85 (88-81)	$I^2 = 79\%$, $\tau^2 = 0.0441$, p < 0.01
2					/	, , , , , , , , , , , , , , , , , , ,

\geq 7 days after dose 2	67 / 9866	596,801 / 1,488,207	98 (99–96)	$I^2 = 84\%, \tau^2 = 0.3136, p < 0.01$	98 (99–95)	$I^2 = 74\%, \tau^2 = 0.2842, p < 0.01$
Beta/Gamma (B.1.3.51 or P.	1)					
≥14 days after dose 1	>50 / 480	181,262 / 1,075,998	_ ^b	$I^2 = 85\%, \tau^2 = 0.6820, p < 0.01$	81 (86–74)	$I^2 = 0\%, \tau^2 = 0, p = 0.75$
≥7 days after dose 2	>0 / 203	230,867 / 818,862	_ ^c		- ^c	
Beta (B.1.351)						
≥14 days after dose 1	>19 / 196	181,262 / 1,075,998	_b	$I^2 = 75\%, \tau^2 = 0.9788, p = 0.02$	63 (78–37)	$I^2 = 0\%, \tau^2 = 0, p = 0.92$
≥7 days after dose 2	>0 / >3	230,867 / 818,862	- ^c		_ c	
Gamma (P.1)						
≥14 days after dose 1	>168 / 1,034	181,262 / 1,075,998	6 (45 to -61)	$I^2 = 85\%$, $\tau^2 = 0.1542$, p < 0.01	76 (80–71)	$I^2 = 0\%, \tau^2 = 0, p = 0.99$
≥7 days after dose 2	>4 / >467	230,867 / 818,862	98 (99–96)	$I^2 = 0\%, \tau^2 = 0, p = 0.58$	96 (99–86)	$I^2 = 58\%, \tau^2 = 0.4345, p = 0.12$
Delta (B.1.617.2)						
≥14 days after dose 1	321 / 3223	194778 / 1,096,618	74 (947)	$I^2 = 99\%$, $\tau^2 = 2.0844$, p < 0.01	89 (95–77)	$I^2 = 94\%, \ \tau^2 = 0.5667, \ p < 0.01$
≥7 days after dose 2	417 / 3319	559071 / 1,460,911	89 (98–35)	$I^2 = 100\%$, $\tau^2 = 3.1280$, p < 0.01	99 (99–97)	$I^2 = 98\%, \tau^2 = 0.6547, p < 0.01$
Interval between doses						
0–6 days after dose 2						
21–34 days	>19 / 32,555	3,155 / 1,404,787	79 (87–66)	$I^2 = 3\%$, $\tau^2 = 0.0133$, p = 0.31	94 (99–38)	$I^2 = 83\%$, $\tau^2 = 2.4291$, p = 0.02
35–55 days	>10/32,551	5,878 / 1,407,510	87 (95–66)	$I^2 = 74\%, \tau^2 = 0.7026, p < 0.01$	91 (95-86)	$I^2 = 0\%, \tau^2 = 0, p = 0.51$
56–83 days	>12 / 13,425	9,359 / 1,104,250	89 (94–77)	$I^2 = 56\%$, $\tau^2 = 0.2723$, p = 0.08	94 (96–89)	$I^2 = 12\%, \tau^2 = 0.0663, p = 0.33$
≥84 days	>16 / 32,553	6,444 / 1,408,076	80 (94–30)	$I^2 = 80\%$, $\tau^2 = 1.2881$, p < 0.01	93 (98–79)	$I^2 = 70\%, \tau^2 = 0.8055, p = 0.02$
7–55 days after dose 2						
21–34 days	29 / 32,627	9,410 / 1,104,301	84 (89–78)	$I^2 = 44\%, \tau^2 = 0.0439, p = 0.15$	94 (96–90)	$I^2 = 71\%, \tau^2 = 0.2059, p = 0.02$
35–55 days	29 / 13,441	37,571 / 1,132,462	97 (99–89)	$I^2 = 94\%$, $\tau^2 = 1.3166$, p < 0.01	98 (99–94)	$I^2 = 86\%, \tau^2 = 1.1059, p < 0.01$
56–83 days	43 / 13,455	109,802 / 1,204,693	96 (98–94)	$I^2 = 74\%, \tau^2 = 0.2187, p = 0.01$	99 (99–97)	$I^2 = 88\%, \tau^2 = 0.4462, p < 0.01$
≥84 days	>48 / 13,463	38,731 / 1,133,622	89 (96–69)	$I^2 = 94\%$, $\tau^2 = 0.9692$, p < 0.01	98 (99–94)	$I^2 = 94\%, \ \tau^2 = 0.9409, \ p < 0.01$
56–111 days after dose 2						
21–34 days	>40 / 32,581	15,620 / 1,417,252	91 (96–79)	$I^2 = 79\%, \tau^2 = 0.5797, p < 0.01$	97 (98–96)	$I^2 = 0\%$, $\tau^2 = 0$, p = 0.63
35–55 days	34 / 32,570	61,129 / 1,462,761	97 (99–93)	$I^2 = 89\%, \tau^2 = 0.7648, p < 0.01$	99 (99–98)	$I^2 = 73\%$, $\tau^2 = 0.3612$, p = 0.01
56–83 days	>135 / 32,675	129,501 / 1,531,133	95 (98-89)	$I^2 = 96\%$, $\tau^2 = 0.5262$, p < 0.01	99 (100–98)	$I^2 = 96\%, \tau^2 = 0.8204, p < 0.01$
≥84 days	>127 / 32,663	46,942 / 1,448,574	86 (96–48)	$I^2 = 98\%$, $\tau^2 = 1.3642$, p < 0.01	99 (100–95)	$I^2 = 98\%$, $\tau^2 = 1.3064$, p < 0.01
≥112 days after dose 2						
21–34 days	>7 / 13,424	5,248 / 1,100,139	86 (94–65)	$I^2 = 80\%$, $\tau^2 = 0.6880$, p < 0.01	97 (99–92)	$I^2 = 71\%, \tau^2 = 0.5472, p = 0.01$
35–55 days	>24 / 32,563	12,805 / 1,414,437	89 (97–66)	$I^2 = 90\%$, $\tau^2 = 0.9139$, p < 0.01	97 (98–95)	$I^2 = 19\%$, $\tau^2 < 0.0001$, p = 0.29
56–83 days	>13 / 13,425	2,522 / 1,097,413	77 (95 to -	$I^2 = 89\%, \tau^2 = 1.7106, p < 0.01$	97 (99–95)	$I^2 = 21\%, \tau^2 = 0.0609, p = 0.28$
			10)			_
≥84 days	>4 / >13,416	11,450 / 1,413,082	97 (99–92)	$I^2 = 6\%, \tau^2 = 0.1071, p = 0.34$	99 (100–97)	$I^2 = 61\%, \tau^2 = 0.9402, p = 0.08$

^aModels adjusted for age group, sex, public health unit region, biweekly period of test, number of SARS-CoV-2 tests in the 3 months prior to 14 December 2020, presence of any comorbidity that increase the risk of severe COVID-19, receipt of influenza vaccination in current or prior influenza season, and neighbourhood income (material deprivation index in British Columbia), proportion of persons employed as non-health essential workers, persons per dwelling, and self-identified visible minority quintiles. Receipt of influenza vaccination was not adjusted for in British Columbia because of lack of data.

^bVE not reported due to extremely imprecise 95% confidence intervals.

^cNot applicable as VE estimate from only one province available.

References:

- Skowronski DM, Setayeshgar S, Febriani Y, Ouakki M, Zou M, Talbot D, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv. 2021:2021.2010.2026.21265397. doi: 10.1101/2021.10.26.21265397.
- 2. Government of Canada. NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada 2021 [cited 2021 3 March]. Available from: <u>https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html.</u>
- 3. National Advisory Committee on Immunization (NACI). NACI: Summary of updated vaccine statement of April 23, 2021. Canada Ottawa, ON: Government of Canada; 2021 [cited 2021 15 May]. Available from: <u>https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-april-23-2021.html.</u>
- National Advisory Committee on Immunization (NACI). NACI rapid response: Interchangeability of authorized COVID-19 vaccines [2021-06-01] Ottawa, ON: Government of Canada; 2021 [cited 2021 29 September]. Available from: <u>https://www.canada.ca/en/publichealth/services/immunization/national-advisory-committee-on-immunizationnaci/recommendations-use-covid-19-vaccines/rapid-response-interchangeability.html.
 </u>
- 5. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. 2022. doi: 10.1038/s41564-021-01053-0.
- 6. The Johns Hopkins ACG system. Baltimore: Johns Hopkins University; [cited 2021 14 July]. Available from: <u>http://www.hopkinsacg.org/</u>.
- 7. British Columbia Centre for Disease Control [creator]. Integrated COVID-19 laboratory dataset (SARS-CoV2 tests from private/public labs). Public Health Reporting Data Warehouse, British Columbia Centre for Disease Control [publisher] (2020). 2021.
- 8. British Columbia Centre for Disease Control [creator]. COVID-19 surveillance case data. British Columbia Centre for Disease Control [publisher]. (2020). 2021.
- 9. Provincial Health Services Authority [creator]. Provincial COVID-19 Monitoring Solution. Provincial Health Services Authority [publisher]. (2020). 2021.
- 10. Provincial Health Services Authority [creator]. COVID-19 vaccination data. Provincial Immunizations Registry, Provincial Public Health Information Systems [publisher]. (2020). 2021.
- 11. Provincial Health Services Authority [creator]. Provincial Public Health Information Systems [publisher]. (2020). 2021.
- 12. British Columbia Centre for Disease Control [creator]. Respiratory datamart, Public Health Reporting Data Warehouse, British Columbia Centre for Disease Control [publisher] (2020). 2021.
- 13. British Columbia Ministry of Health [creator]. Client Roster (Client Registry System/Enterprise Master Patient Index). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. <u>https://www2.gov.bc.ca/gov/content/health/health-forms/online-services</u>.
- 14. British Columbia Ministry of Health [creator]. Discharge Abstract Database (Hospital Separations). British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. <u>https://www2.gov.bc.ca/gov/content/health/health-forms/online-services</u>.
- 15. British Columbia Ministry of Health [creator]. Medical Services Plan (MSP) Payment Information File. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021.<u>https://www2.gov.bc.ca/gov/content/health/health-forms/online-services</u>.
- 16. British Columbia Ministry of Health [creator]. PharmaNet. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. <u>https://www2.gov.bc.ca/gov/content/health/health-forms/online-services</u>.

- BC Vital Statistics Agency [creator]. Vital Statistics Deaths. BC Vital Statistics Agency [publisher]. Data Extract. BC Vital Statistics Agency (2020). 2021. https://www2.gov.bc.ca/gov/content/health/health-forms/online-services.
- 18. British Columbia Ministry of Health [creator]. National Ambulatory Care Reporting System. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. https://www2.gov.bc.ca/gov/content/health/health-forms/online-services.
- 19. British Columbia Ministry of Health [creator]. Chronic Disease Registry. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2020. https://www2.gov.bc.ca/gov/content/health/health-forms/online-services.
- 20. British Columbia Ministry of Health [creator]. 811 calls. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. <u>https://www2.gov.bc.ca/gov/content/health/health-forms/online-services</u>.
- 21. British Columbia Ministry of Health [creator]. Health System Matrix. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. https://www2.gov.bc.ca/gov/content/health/health-forms/online-services.
- 22. British Columbia Ministry of Health [creator]. Population Grouper Methodology. British Columbia Ministry of Health [publisher]. Data Extract. MOH (2020). 2021. https://www2.gov.bc.ca/gov/content/health/health-forms/online-services.